## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2020-04-22_Virtual Town Hall 5_fixnames.md
last updated: 2024-12-31 Created QA Sections
link pdf: https://www.fda.gov/media/137426/download?attachment
link youtube: https://youtu.be/bo40H5RSmGg
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Updates on SARS-CoV-2 Testing Approvals and Procedures

QA Block 1-1
CLARIFIED QUESTION: What are the specific validation steps required for using Q-tip style cotton swabs in COVID-19 testing?
CLARIFIED ANSWER: The FDA requires extensive quality control testing for each lot of kits using Q-tip style cotton swabs and advises developers to assess performance impacts such as sensitivity effects near the limit of detection.
VERBATIM QUESTION: What are the specific validation steps required for using Q-tip style cotton swabs in COVID-19 testing?
VERBATIM ANSWER: We also because of the particular swap type they use - it's a Q-tip style cotton swab - that we asked them to do a fairly extensive quality control testing of each lot of kits. So while the cotton Q-tip style swab is now authorized for one entity, we would urge anyone who wants to consider a Q-tip style cotton swab that they carefully look at whether that affects their testing performance at all. Does it impact the sensitivity near LOD? Does it impact the sensitivity? And that is perhaps not an ideal swap type to use but obviously we felt under the conditions of authorization for LabCorp that we're appropriately protecting patients and ensuring accurate testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 testing validation, Q-tip style cotton swabs, Testing sensitivity
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: Does a developer need to validate changes to their swab media if using a new manufacturer's alternative product?
CLARIFIED ANSWER: Developers must validate changes to swab media according to their CLIA SOPs but do not need an EUA update. Sharing the data with FDA is voluntary and encouraged.
VERBATIM QUESTION: Does a developer need to validate changes to their swab media if using a new manufacturer's alternative product?
VERBATIM ANSWER: In regards to that, I did want to briefly remind everyone of some of the details of our March 16th updated guidance for labs who want to make certain modifications such as a change in swab media, extraction reagents, and PCR instruments. I simply do an unintelligible other bridging study that's appropriate under their own CLIA SOPs and compliant with CLIA. They can implement those changes without a EUA update. And we would love to see that on a voluntary basis so that we can perhaps make it more well-known. If you are adopting any swab, for a new manufacturer say, we would love to see that information but it's not required.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation of swab media changes, EUA update requirements, Developer responsibilities
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: What are the requirements for laboratories to modify PCR instruments under their CLIA SOPs without needing a EUA update?
CLARIFIED ANSWER: Laboratories can modify PCR instruments if they perform an appropriate bridging study compliant with their CLIA SOPs. These changes can be made without an EUA update, although sharing such modifications with the FDA on a voluntary basis is encouraged.
VERBATIM QUESTION: What are the requirements for laboratories to modify PCR instruments under their CLIA SOPs without needing a EUA update?
VERBATIM ANSWER: In regards to that, I did want to briefly remind everyone of some of the details of our March 16th updated guidance for labs who want to make certain modifications such as a change in swab media, extraction reagents, and PCR instruments. I simply do an unintelligible other bridging study that's appropriate under their own CLIA SOPs and compliant with CLIA. They can implement those changes without a EUA update. And we would love to see that on a voluntary basis so that we can perhaps make it more well-known.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: PCR Instrument Modifications, CLIA Compliance, EUA Guidance
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: In the absence of a EUA update requirement, what kind of bridging study is acceptable for labs modifying their swab media or reagents?
CLARIFIED ANSWER: Labs can perform a bridging study under their CLIA SOPs, compliant with CLIA, to modify swab media or reagents without requiring an EUA update. Providing data voluntarily is appreciated but not required.
VERBATIM QUESTION: In the absence of a EUA update requirement, what kind of bridging study is acceptable for labs modifying their swab media or reagents?
VERBATIM ANSWER: I simply do an unintelligible other bridging study that's appropriate under their own CLIA SOPs and compliant with CLIA. They can implement those changes without a EUA update. And we would love to see that on a voluntary basis so that we can perhaps make it more well-known.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA updates, Laboratory bridging studies, CLIA compliance
REVIEW FLAG: True

QA Block 1-5
CLARIFIED QUESTION: When will updated instructions for Abbott ID Now tests reflecting removal of VTM as a sample type be available?
CLARIFIED ANSWER: The FDA is working to update the instructions for the Abbott ID Now test on their website soon, emphasizing that VTM should no longer be used and the direct swab method should be followed.
VERBATIM QUESTION: When will updated instructions for Abbott ID Now tests reflecting removal of VTM as a sample type be available?
VERBATIM ANSWER: I think we're trying to get the instructions for use update onto our website soon. Again, VTM as a sample type should no longer be used with the Abbott ID Now. Rather, the direct swab approach is one that should be followed.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Instructions for Abbott ID Now, VTM removal, Direct swab method
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: Are there new specific optional extraction chemistries added to the FDA-approved list for COVID-19 tests?
CLARIFIED ANSWER: The FDA has added new optional extraction chemistries, including the Kingfisher and its RUO equivalent, the MagMAX, which are available through Thermofisher.
VERBATIM QUESTION: Are there new specific optional extraction chemistries added to the FDA-approved list for COVID-19 tests?
VERBATIM ANSWER: Some of the key updates that we made are that we have increased the number of the optional extraction chemistries, we've added the Kingfisher along with the RUO equivalent of the Kingfisher, the MagMAX. And those I believe are available through Thermofisher.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 test updates, Extraction chemistries, Kingfisher and MagMAX
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: Are there additional requirements for submitting voluntary validations of alternate cotton swab types to the FDA?
CLARIFIED ANSWER: The FDA welcomes voluntary submission of validation data for alternate cotton swab types and is open to discussions with developers.
VERBATIM QUESTION: Are there additional requirements for submitting voluntary validations of alternate cotton swab types to the FDA?
VERBATIM ANSWER: If you voluntarily want to show us any of your validation around these alternate cotton swab types, we would be happy to engage in a conversation with you.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: voluntary submission, validation of cotton swabs
REVIEW FLAG: False

QA Block 1-8
CLARIFIED QUESTION: What considerations must be evaluated for saliva as a sample type to gain regulatory approval for COVID-19 testing?
CLARIFIED ANSWER: The FDA is evaluating saliva as a sample type for COVID-19 testing and notes that a suitable preservative may be needed to maintain RNA integrity and eliminate RNases. However, some preservatives may be toxic, making safety and accuracy critical considerations. Developers should engage with the FDA to assess these factors, as existing data is variable and has not yet supported authorization.
VERBATIM QUESTION: What considerations must be evaluated for saliva as a sample type to gain regulatory approval for COVID-19 testing?
VERBATIM ANSWER: We are continuing to take a look at saliva as a sample type. We believe that a preservative may be necessary that preserve the integrity of the RNA. It may destroy RNases. Some of the preservatives that are capable of doing that are potentially toxic, so that is an important consideration in addition to the accuracy. And we would ask that developers who are considering saliva as a sample type, that they come in and to discuss those opportunities with the FDA. And that we together can assess the accuracy and the safety of such a sample type. Some of the data we have seen today has been variable and we have not been able to authorize based on existing data. And we are still trying to assess what the variables are around an adequate saliva sample that ensures accurate and safe testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva as sample type, Regulatory considerations, COVID-19 testing
REVIEW FLAG: False

QA Block 1-9
CLARIFIED QUESTION: What are the FDA's expectations regarding home collection kits before launching them under EUA?
CLARIFIED ANSWER: FDA requires home collection and testing kits to receive authorization before launching under EUA to ensure patient safety and testing accuracy.
VERBATIM QUESTION: What are the FDA's expectations regarding home collection kits before launching them under EUA?
VERBATIM ANSWER: I would still remind all that home collection and/or home testing requires an FDA authorization before launching the EUA authorization. And this is to ensure that patients in the home, that safety is considered and that testing is accurate.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home collection kits, FDA expectations, EUA requirements
REVIEW FLAG: False

QA Block 1-10
CLARIFIED QUESTION: Can two serology tests be combined to improve positive predictive value, and what performance results would be acceptable for this setup?
CLARIFIED ANSWER: Combining two serology tests back-to-back can improve positive predictive value significantly. For instance, two highly specific tests (99%) can yield a positive predictive value of 98.9% in a 1% prevalent population. Using a 95% specific test followed by a 99% specific test achieves a value of 94.5%.
VERBATIM QUESTION: Can two serology tests be combined to improve positive predictive value, and what performance results would be acceptable for this setup?
VERBATIM ANSWER: One thing that we're examining is if you combine two serology tests back-to-back and you require a positive for both serology tests, how does that impact the positive predictive value. If you take two highly specific tests and that FDA same lower and bound of the confidence interval is 99% and you have the same 1% population, the positive predictive value rises to 98.9% -- a pretty decent number. Even if you start out with the lower serology test that has a specificity of 95% but follow it up with a more specific test such as 99% specific in a 1% prevalent population, your positive predictive value rises to 94.5%. So just under 95% -- also a fairly decent number. So I thought it was important to go over their performance characteristics of tests and how they're applied to populations and what a positive result can really mean and perhaps the importance of doing a confirmation serology test if the information from a serology test is important to you.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology testing, Positive predictive value, Combining diagnostics
REVIEW FLAG: False

QA Block 1-12
CLARIFIED QUESTION: How does the FDA prioritize complaints about tests and address incidents leading to concerns about product performance or fraud?
CLARIFIED ANSWER: The FDA addresses complaints about inappropriate marketing or fraud via a dedicated fraud email and through their active MedWatch system, where reported issues are reviewed, and appropriate decisions are made.
VERBATIM QUESTION: How does the FDA prioritize complaints about tests and address incidents leading to concerns about product performance or fraud?
VERBATIM ANSWER: I want to just move on quickly to one other thing and that is they continue to hear complaints about inappropriate marketing or perhaps fraud. We do have a fraud email. We appreciate all submissions to that email. And also I would also remind you that we have an active MedWatch going. You can go to the MedWatch FDA site and report any problems you see. We do review those complaints and those data and make appropriate decisions based on it.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Complaints about tests, Fraud in marketing, FDA MedWatch system
REVIEW FLAG: False

QA Block 1-13
CLARIFIED QUESTION: What's the role of 95% confidence interval lower bounds in the performance evaluation of serology tests?
CLARIFIED ANSWER: The FDA requires 95% confidence interval calculations to evaluate sensitivity and specificity. The lower bound is closely examined because small sample sizes can result in wider intervals, potentially lowering the lower bound. Larger studies help narrow these intervals, providing more reliable data. The lower bound is critical for assessing the full range of possible results.
VERBATIM QUESTION: What's the role of 95% confidence interval lower bounds in the performance evaluation of serology tests?
VERBATIM ANSWER: When we measure sensitivity and specificity, we do require calculations of the 95% confidence interval. And we do look closely at the lower bound of the 95% confidence interval because for any given sample size involved in testing, the smaller the sample size the greater potentially the spread of the 95% confidence interval. So for example, you may actually measure a fairly high specificity but if the sample size is low, the lower bound of the 95% confidence interval can be quite low. That is why we always favor larger studies over smaller studies. Some of the high volume, high-throughput serology central lab tests that we've seen the data on -- one of which we've already authorized -- tests more than a thousand patients for specificity determination. Obviously when you test that many patients, your 95% confidence interval is going to be even more narrow. FDA However, even though it's narrower, the lower end of the 95th percentile confidence interval is important for looking at the full range of possible results.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test evaluation, 95% confidence interval, test performance
REVIEW FLAG: False

QA Block 1-14
CLARIFIED QUESTION: How is the public-private partnership led by the FDA improving terminology consistency for diagnostic test reporting (such as SARS-CoV-2)?
CLARIFIED ANSWER: FDA's public-private partnership is addressing inconsistent reporting by standardizing how diagnostic tests, including SARS-CoV-2 and serological tests, are described from laboratories. Terminology codes are being developed for uniform test descriptions, enabling better aggregation, analysis, and validation of data in real-time.
VERBATIM QUESTION: How is the public-private partnership led by the FDA improving terminology consistency for diagnostic test reporting (such as SARS-CoV-2)?
VERBATIM ANSWER: Great. Thank you, Tim. I'll give a brief update on the topic of laboratory data harmonization. In this context, it's sometimes an overlooked but really essential aspect of understanding how many infections we have in the country at any given time. The detection of the emergence, prevalence, and spread of FDA infectious diseases is essential to inform efforts to protect and preserve public health from the local, state, and national levels. So currently surveillance efforts are hindered due to inabilities to pool and compare data derived from laboratory diagnostics unless consistent reporting practices have been adopted electronically. At the core of this problem is a fundamental inconsistency and how tests are described where we're seeing with SARS-CoV-2 diagnostics, for example, the same test or a test meant to give the same type of answer is often described in different ways, which leads to ambiguities in the meaning of that information as well as an inability to roll it up or aggregate that data and understand it and analyze it collectively. So as part of a public-private partnership, the FDA and APHL manufacturers, labs standards developers, CDC, and other agencies across HHS are working to ensure that molecular diagnostic testing for SARS-CoV-2 as well as serological testing can be described the same way from the get-go right out of the lab. The terminology codes are currently being developed and assigned to each test to represent the question that the test asks of each specimen and the range of answers that can be generated from that test. This information will be extremely important in terms of addressing shortages for testing, ensuring that tests are working the way that they're intended to, and better understanding their performance in the field moving forward and expediting ways to validate and interpret how therapeutic or clinical interventions are actually working in terms of health outcomes as we move forward. So simply by describing our diagnostic tests the same way from the get-go, the data generated from those tests can be used to gather more detailed information in real-time that will help us protect the nation and get back on FDA our feet. We have email address that inquiries can be sent to. The email address that you can reach out to us at is SHIELD-LabCodes@fda.hhs.gov. That will be able to receive emails tomorrow, so hold off on emailing us until tomorrow if you're interested in this information and would like to participate in this effort. Thank you.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Sara Brenner (FDA)
TOPICS: Terminology consistency, Diagnostic test reporting, Public-private partnership
REVIEW FLAG: False

QA Block 1-15
CLARIFIED QUESTION: What standardization steps are required to describe SARS-CoV-2 diagnostic and serology tests for interoperability across laboratories?
CLARIFIED ANSWER: The FDA, in partnership with various organizations, is addressing inconsistent reporting of SARS-CoV-2 test data by developing standardized terminology codes. These codes ensure all diagnostic and serological tests are described uniformly, enabling better data aggregation, analysis, and interoperability.
VERBATIM QUESTION: What standardization steps are required to describe SARS-CoV-2 diagnostic and serology tests for interoperability across laboratories?
VERBATIM ANSWER: Currently surveillance efforts are hindered due to inabilities to pool and compare data derived from laboratory diagnostics unless consistent reporting practices have been adopted electronically. At the core of this problem is a fundamental inconsistency and how tests are described where we're seeing with SARS-CoV-2 diagnostics, for example, the same test or a test meant to give the same type of answer is often described in different ways, which leads to ambiguities in the meaning of that information as well as an inability to roll it up or aggregate that data and understand it and analyze it collectively. So as part of a public-private partnership, the FDA and APHL manufacturers, labs standards developers, CDC, and other agencies across HHS are working to ensure that molecular diagnostic testing for SARS-CoV-2 as well as serological testing can be described the same way from the get-go right out of the lab. The terminology codes are currently being developed and assigned to each test to represent the question that the test asks of each specimen and the range of answers that can be generated from that test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Sara Brenner (FDA)
TOPICS: standardization, SARS-CoV-2 diagnostics, data harmonization
REVIEW FLAG: False

QA Block 1-16
CLARIFIED QUESTION: What are the expected performance levels of specificity and sensitivity in serology tests for lower prevalence populations, according to the FDA?
CLARIFIED ANSWER: For serology tests, specificity and sensitivity are critical, especially in low-prevalence populations. A test with 99% specificity in a 1% prevalence population has a positive predictive value (PPV) of 49%. For tests with 95% specificity, PPV drops to 15.4%. By combining a 95% specific test with a more specific 99% test, the PPV can improve to 94.5%, demonstrating the value of confirmatory testing.
VERBATIM QUESTION: What are the expected performance levels of specificity and sensitivity in serology tests for lower prevalence populations, according to the FDA?
VERBATIM ANSWER: When we talk about performance, we talk about what is the sensitivity of the assay, what is the specificity of the assay. And at times, depending on what the comparative is, we call sensitivity percent positive agreement and sometimes they call a specificity negative percent agreement. Those are just an initial look at what performance is. It's also important -- and I believe especially for serology tests -- to understand what the prevalence of disease is as far as the impact on the actual clinical testing performance and what the clinical testing results mean. We look at things such as positive predictive value and negative predictive value to tell us in certain populations what is the impact of testing and in fact what is the impact of actual sensitivity and specificity. When we measure sensitivity and specificity, we do require calculations of the 95% confidence interval. And we do look closely at the lower bound of the 95% confidence interval because for any given sample size involved in testing, the smaller the sample size the greater potentially the spread of the 95% confidence interval. So for example, you may actually measure a fairly high specificity but if the sample size is low, the lower bound of the 95% confidence interval can be quite low. That is why we always favor larger studies over smaller studies. Some of the high volume, high-throughput serology central lab tests that we've seen the data on -- one of which we've already authorized -- tests more than a thousand patients for specificity determination. Obviously when you test that many patients, your 95% confidence interval is going to be even more narrow. However, even though it's narrower, the lower end of the 95th percentile confidence interval is important for looking at the full range of possible results. And I would say that you know, some of the specificities are quite high, you know, in the mid-99 percentile-- so 99.5, 99.6 -- in the lower bound is around 99%. If you look at positive predictive value in a population that has a prevalence of 1% we don't yet know what the actual prevalence of COVID-19 is across all of our communities in the United States and as an overall measure. Those efforts are underway and those efforts are very important for us to understand how to apply a given test sensitivity and specificity to your specific situation. But I just wanted to give a couple of performance numbers so that you understand the impact of prevalence and specificity on actual positive predictive values. Positive predictive value is a measure of how many times out of a hundred is a positive result, a true positive. So if you take a test that is 99% specific -- and I'm using the lower end of the 95% confidence interval here -- and you measure it in a population that has a 1% prevalence of disease, your positive predictive value is 49%. That means only 49 times out of 100 is that positive result a true positive. The rest of the time it is a false-positive result. You might falsely assume a patient developed an immune response to SARS-CoV-2. If you reduce the specificity of 95% -- that same prevalence of 1% -- the positive predictive value falls to 15.4%. Only 15 times out of 100 is that positive result a true positive. One thing that we're examining is if you combine two serology tests back-to- back and you require a positive for both serology tests, how does that impact the positive predictive value. If you take two highly specific tests and that same lower and bound of the confidence interval is 99% and you have the same 1% population, the positive predictive value rises to 98.9% -- a pretty decent number. Even if you start out with the lower serology test that has a specificity of 95% but follow it up with a more specific test such as 99% specific in a 1% prevalent population, your positive predictive value rises to 94.5%. So just under 95% -- also a fairly decent number.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test sensitivity, Specificity in low prevalence populations, Predictive positive value
REVIEW FLAG: False

QA Block 1-17
CLARIFIED QUESTION: What is the timeline for the FDA's release of its serology testing template on the EUA website?
CLARIFIED ANSWER: The FDA is nearly completed with the serology testing template and will make it available on the website once it is cleared with all appropriate internal parties.
VERBATIM QUESTION: What is the timeline for the FDA's release of its serology testing template on the EUA website?
VERBATIM ANSWER: I would also say that we are nearly completed with a serology template that can be made public on our website. And look for those on our website to be made available as soon as we clear those with all appropriate parties internally.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology testing template, FDA EUA website update
REVIEW FLAG: False

QA Block 1-19
CLARIFIED QUESTION: Are there international efforts guided by FDA to harmonize the testing validation of serological and other COVID-19-related diagnostics?
CLARIFIED ANSWER: The FDA is collaborating internationally to assess the performance of serology and other diagnostics, and it will investigate if tests are found to be inaccurate or unsafe.
VERBATIM QUESTION: Are there international efforts guided by FDA to harmonize the testing validation of serological and other COVID-19-related diagnostics?
VERBATIM ANSWER: We are also connected to other international efforts to assess performance across not just serology tests but other tests as well. I would say that if we come into information that indicates that certain tests are not performing as expected and potentially are putting accurate results at risk or safety at risk, we will investigate all of those.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: international collaboration, serological test validation, test safety
REVIEW FLAG: False

QA Block 1-20
CLARIFIED QUESTION: What methodology is being utilized in the interagency collaboration to streamline EUA for serology tests validated as high-performing?
CLARIFIED ANSWER: The interagency collaboration involves entities like the CDC, NCI, NIH, BARDA, and the FDA. Manufacturers meeting a high bar of performance during interagency testing will be offered a streamlined approach to EUA authorization.
VERBATIM QUESTION: What methodology is being utilized in the interagency collaboration to streamline EUA for serology tests validated as high-performing?
VERBATIM ANSWER: We will in all likelihood offer those manufacturers who pass a certain bar of performance in this interagency testing a somewhat streamlined approach to EUA authorization. And that is one clear way that we can make the testing performance measured by this interagency team available to the public. This interagency collaboration involves careful and great collaboration with entities such as the CDC, NCI, NIH, and BARDA and the FDA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Interagency collaboration, Serology test EUA process
REVIEW FLAG: False


#### 2. Pathway Development for Home Testing and Collection

QA Block 2-1
CLARIFIED QUESTION: Will a pathway be created for home COVID-19 tests?
CLARIFIED ANSWER: FDA is developing templates for home collection and testing, but they are not ready yet. Developers are encouraged to send inquiries for collaboration.
VERBATIM QUESTION: Will a pathway be created for home COVID-19 tests?
VERBATIM ANSWER: We are working on templates that could be used for home collection and home testing but they are not near ready yet to share. In the interim, we asked developers to send us their inquiries at CDRH-EUA- templates@fda.hhs.gov. As appropriate we're happy to jump on a call and talk through the issues that we see and collaboratively work on a steady design to FDA show that testing is accurate.
SPEAKER QUESTION: Douglas Ross
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home testing pathway, COVID-19 diagnostics, template development
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: Is there an estimate for when templates for home collection and home testing might be ready?
CLARIFIED ANSWER: FDA is actively discussing, aligning, and vetting templates for home collection and home testing to ensure accuracy, safety, and feasibility. They are a priority but not yet ready, with no specific timeline provided.
VERBATIM QUESTION: Is there an estimate for when templates for home collection and home testing might be ready?
VERBATIM ANSWER: We've been actively discussing this and aligning internally for a while now as we engage with test developers in this area. Before we make something public, we want to make sure that we've properly vetted it so that it represents our best foot forward on just the right balance between ensuring accurate testing and safe testing and not being burdensome. So as soon as we can. It is a priority.
SPEAKER QUESTION: Douglas Ross
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home testing templates, timelines, FDA approval processes
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: What steps should developers take while awaiting finalized templates for home collection and home testing?
CLARIFIED ANSWER: While finalized templates for home collection and testing are under development, developers should send their inquiries to the FDA's specified email and collaborate with the FDA on test design as needed.
VERBATIM QUESTION: What steps should developers take while awaiting finalized templates for home collection and home testing?
VERBATIM ANSWER: We're striving to get the serology templates out as soon as possible. Maybe even today. That would be awesome. We are working on templates that could be used for home collection and home testing but they are not near ready yet to share. In the interim, we asked developers to send us their inquiries at CDRH-EUA- templates@fda.hhs.gov. As appropriate we're happy to jump on a call and talk through the issues that we see and collaboratively work on a steady design to FDA show that testing is accurate.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home testing templates, developer guidance, interim steps
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: How can developers engage with the FDA to address challenges in home test designs?
CLARIFIED ANSWER: Developers can send inquiries to CDRH-EUA-templates@fda.hhs.gov, and the FDA is open to discussing challenges via calls to collaboratively ensure accurate test designs.
VERBATIM QUESTION: How can developers engage with the FDA to address challenges in home test designs?
VERBATIM ANSWER: In the interim, we asked developers to send us their inquiries at CDRH-EUA-templates@fda.hhs.gov. As appropriate we're happy to jump on a call and talk through the issues that we see and collaboratively work on a steady design to FDA show that testing is accurate.
SPEAKER QUESTION: Douglas Ross
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home test development, FDA guidance, developer inquiries
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: What specific elements are being considered by the FDA to balance accuracy and safety of home testing templates?
CLARIFIED ANSWER: The FDA is carefully coordinating and vetting its approach to ensure home testing templates balance accuracy, safety, and minimal burden.
VERBATIM QUESTION: What specific elements are being considered by the FDA to balance accuracy and safety of home testing templates?
VERBATIM ANSWER: We've been actively discussing this and aligning internally for a while now as we engage with test developers in this area. Before we make something public, we want to make sure that we've properly vetted it so that it represents our best foot forward on just the right balance between ensuring accurate testing and safe testing and not being burdensome.
SPEAKER QUESTION: Douglas Ross
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home testing templates, accuracy and safety, FDA priorities
REVIEW FLAG: False


#### 3. Capillary Blood Versus Venipuncture in Serology Testing Debate

QA Block 3-1
CLARIFIED QUESTION: Are you still taking the position that there is no scientific evidence that capillary blood is equal to venipuncture blood for rapid serology test kits?
CLARIFIED ANSWER: The FDA encourages developers to submit data for evaluating equivalency of fingerstick and venipuncture for serology tests. Templates will provide guidance on the minimum data needed, and one test has been authorized with post-market studies to assess performance.
VERBATIM QUESTION: Are you still taking the position that there is no scientific evidence that capillary blood is equal to venipuncture blood for rapid serology test kits?
VERBATIM ANSWER: Yes, that's a great question. So we welcome all developers to come forward and show us their data for point-of-care testing. Fingerstick may not be required for point-of-care testing if there is the ability to do a venipuncture. We're open to fingerstick as a sample type. And our serology templates, once they're published, will describe publicly what we think the minimum number of patients are to demonstrate the equivalency, the matrix equivalency between venipuncture and fingerstick or serum and plasma and fingerstick. So that hopefully will be posted very soon for all to see. So we are a data-driven organization that requires submission of data for us to review. We have given the opportunity for one authorized test to do fingerstick. They have actually agreed to do follow-on post-market study for the minimum number of fingersticks required for us to assess the performance there. We also have invited them and others to do the usability study from the point- of-care to show that lay users, non-laboratorians, can perform accurate testing. So we do welcome submissions for those uses and are fully willing to authorize them.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Capillary vs venipuncture blood, Serology test authorization, Data submission requirements
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: Are you still taking the position that licensed health professionals like physicians, nurse practitioners, or PAs cannot administer rapid test kits outside of a CLIA complex lab?
CLARIFIED ANSWER: FDA stated that point-of-care tests, including fingerstick methods, may be approved if supported by data. They invited submissions to ensure performance equivalency between capillary and venipuncture methods and noted that usability and layperson use are being studied.
VERBATIM QUESTION: Are you still taking the position that licensed health professionals like physicians, nurse practitioners, or PAs cannot administer rapid test kits outside of a CLIA complex lab?
VERBATIM ANSWER: Yes, that's a great question. So we welcome all developers to come forward and show us their data for point-of-care testing. Fingerstick may not be required for point-of-care testing if there is the ability to do a venipuncture. We're open to fingerstick as a sample type. And our serology templates, once they're published, will describe publicly what we think the minimum number of patients are to demonstrate the equivalency, the matrix equivalency between venipuncture and fingerstick or serum and plasma and fingerstick. So that hopefully will be posted very soon for all to see. So we are a data-driven organization that requires submission of data for us to review. We have given the opportunity for one authorized test to do fingerstick. They have actually agreed to do follow-on post-market study for the minimum number of fingersticks required for us to assess the performance there. We also have invited them and others to do the usability study from the point- of-care to show that lay users, non-laboratorians, can perform accurate testing. So we do welcome submissions for those uses and are fully willing to authorize them.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: point-of-care testing approvals, fingerstick vs venipuncture equivalency, usability testing for rapid tests
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: What data is required to demonstrate the equivalency between venipuncture and fingerstick blood for COVID-19 serology tests?
CLARIFIED ANSWER: The FDA will outline in its serology templates the minimum data required to demonstrate equivalency between venipuncture and fingerstick blood, with a focus on matrix equivalency and patient numbers. Submission of evidence and usability studies are encouraged.
VERBATIM QUESTION: What data is required to demonstrate the equivalency between venipuncture and fingerstick blood for COVID-19 serology tests?
VERBATIM ANSWER: Yes, that's a great question. So we welcome all developers to come forward and show us their data for point-of-care testing. Fingerstick may not be required for point-of-care testing if there is the ability to do a venipuncture. We're open to fingerstick as a sample type. And our serology templates, once they're published, will describe publicly what we think the minimum number of patients are to demonstrate the equivalency, the matrix equivalency between venipuncture and fingerstick or serum and plasma and fingerstick. So that hopefully will be posted very soon for all to see. So we are a data-driven organization that requires submission of data for us to review. We have given the opportunity for one authorized test to do fingerstick. They have actually agreed to do follow-on post-market study for the minimum number of fingersticks required for us to assess the performance there. We also have invited them and others to do the usability study from the point- of-care to show that lay users, non-laboratorians, can perform accurate testing. So we do welcome submissions for those uses and are fully willing to authorize them.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Equivalency criteria, Venipuncture vs fingerstick, Serology test data
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: What is the minimum number of patients needed in studies to show sample type equivalency for serology tests?
CLARIFIED ANSWER: The FDA will publish serology templates outlining the minimum number of patients required to demonstrate sample type equivalency, which will be available soon.
VERBATIM QUESTION: What is the minimum number of patients needed in studies to show sample type equivalency for serology tests?
VERBATIM ANSWER: Our serology templates, once they're published, will describe publicly what we think the minimum number of patients are to demonstrate the equivalency, the matrix equivalency between venipuncture and fingerstick or serum and plasma and fingerstick. So that hopefully will be posted very soon for all to see.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology sample equivalency, minimum patients needed, FDA serology templates
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: What information will be included in the FDA serology templates for developers?
CLARIFIED ANSWER: The FDA serology templates will outline the minimum number of patients needed to demonstrate matrix equivalency between venipuncture, fingerstick, serum, and plasma.
VERBATIM QUESTION: What information will be included in the FDA serology templates for developers?
VERBATIM ANSWER: And our serology templates, once they're published, will describe publicly what we think the minimum number of patients are to demonstrate the equivalency, the matrix equivalency between venipuncture and fingerstick or serum and plasma and fingerstick.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology templates, matrix equivalency, diagnostic testing requirements
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: Can a developer submit data for tests that include fingerstick as an alternative sample type?
CLARIFIED ANSWER: FDA encourages developers to submit data regarding fingerstick tests as an alternative sample type, as long as data supporting equivalency with venipuncture is provided. FDA templates will soon clarify requirements.
VERBATIM QUESTION: Can a developer submit data for tests that include fingerstick as an alternative sample type?
VERBATIM ANSWER: Yes, that's a great question. So we welcome all developers to come forward and show us their data for point-of-care testing. Fingerstick may not be required for point-of-care testing if there is the ability to do a venipuncture. We're open to fingerstick as a sample type. And our serology templates, once they're published, will describe publicly what we think the minimum number of patients are to demonstrate the equivalency, the matrix equivalency between venipuncture and fingerstick or serum and plasma and fingerstick. So that hopefully will be posted very soon for all to see. So we are a data-driven organization that requires submission of data for us to review. We have given the opportunity for one authorized test to do fingerstick. They have actually agreed to do follow-on post-market study for the minimum number of fingersticks required for us to assess the performance there. We also have invited them and others to do the usability study from the point-of-care to show that lay users, non-laboratorians, can perform accurate testing. So we do welcome submissions for those uses and are fully willing to authorize them.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Fingerstick as sample type, Test data submission, FDA serology templates
REVIEW FLAG: False

QA Block 3-7
CLARIFIED QUESTION: What are the specific post-market study requirements for tests involving fingersticks?
CLARIFIED ANSWER: The FDA requires follow-on post-market studies to assess the performance of fingerstick tests and usability studies to demonstrate that non-laboratorians can perform accurate testing.
VERBATIM QUESTION: What are the specific post-market study requirements for tests involving fingersticks?
VERBATIM ANSWER: We have given the opportunity for one authorized test to do fingerstick. They have actually agreed to do follow-on post-market study for the minimum number of fingersticks required for us to assess the performance there. We also have invited them and others to do the usability study from the point-of-care to show that lay users, non-laboratorians, can perform accurate testing.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: post-market studies, fingerstick testing, usability requirements
REVIEW FLAG: False

QA Block 3-8
CLARIFIED QUESTION: What performance data is required to authorize tests that use lay users or non-laboratorians?
CLARIFIED ANSWER: The FDA requires usability studies from point-of-care settings to demonstrate that lay users or non-laboratorians can perform accurate testing. They welcome submissions for these uses and are willing to authorize them based on adequate data.
VERBATIM QUESTION: What performance data is required to authorize tests that use lay users or non-laboratorians?
VERBATIM ANSWER: We also have invited them and others to do the usability study from the point-of-care to show that lay users, non-laboratorians, can perform accurate testing. So we do welcome submissions for those uses and are fully willing to authorize them.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Lay user testing, Performance data, Test authorization
REVIEW FLAG: False


#### 4. FDA's Focus on Point-of-Care Test Authorization

QA Block 4-1
CLARIFIED QUESTION: Where will there be prioritization of serology tests that can perform high-specificity and high-sensitivity point-of-care testing in the coming weeks and this year?
CLARIFIED ANSWER: The FDA is prioritizing authorization of point-of-care serology tests, including ensuring they can provide accurate results in settings without trained laboratory professionals. They require data proving test performance (e.g., sensitivity, specificity) and equivalency between sample types. FDA stresses the need for confirmatory testing to address any uncertainties in clinical decisions.
VERBATIM QUESTION: Where will there be prioritization of serology tests that can perform high-specificity and high-sensitivity point-of-care testing in the coming weeks and this year?
VERBATIM ANSWER: So we are very interested in authorizing point-of-care tests -- both molecular and serology. As I said in response to the last question, we want to see the data that accurate testing can be performed in the point of care testing site in a wave setting with users that are not trained laboratory professionals. And if fingerstick is an important element of that point of care setting, to be able to see data show the equivalency for that particular test between point of care - I mean fingerstick and another sample type that's also been evaluated. So we think this is possible. Our template will describe some minimum performance characteristics that we need to be able to see such as sensitivity and specificity. And an example is if specificity is not high enough, we would want to understand why that is. And perhaps more cross-reactivity testing with known potential cross-reacting respiratory pathogens may be required to understand the performance of that test. As I said in my introductory remarks though, even if you have a very highly specific test - one of these very high-quality, high-throughput central lab tests which have studied over 1000 patients - the lower end of the confidence interval at 99% in certain populations may not be alone high enough to make important clinical decisions for that patient. And confirmatory serology testing may the important element serology testing -- making a decision based on even a high-performing test may not be sufficient to ensure that you know what really happened with that patient. Hopefully, that addresses your FDA question. I would also add that performance at the point of care potentially could be a little bit lower as long as it's reflexed for confirmation to a higher-performing central lab test.
SPEAKER QUESTION: Julie Leslie
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care serology tests, Sensitivity and specificity, Confirmatory testing
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: What are the data requirements for demonstrating that accurate testing can be performed in a point-of-care setting by non-laboratory professionals?
CLARIFIED ANSWER: FDA is interested in authorizing point-of-care molecular and serology tests, needing data that shows accurate testing can be performed at point-of-care settings by non-laboratory professionals. If fingerstick samples are involved, data should establish equivalency with other sample types. Testing should meet minimum performance characteristics like sensitivity and specificity, with further cross-reactivity testing required in cases of low specificity.
VERBATIM QUESTION: What are the data requirements for demonstrating that accurate testing can be performed in a point-of-care setting by non-laboratory professionals?
VERBATIM ANSWER: So we are very interested in authorizing point-of-care tests -- both molecular and serology. As I said in response to the last question, we want to see the data that accurate testing can be performed in the point of care testing site in a wave setting with users that are not trained laboratory professionals. And if fingerstick is an important element of that point of care setting, to be able to see data show the equivalency for that particular test between point of care - I mean fingerstick and another sample type that's also been evaluated. So we think this is possible. Our template will describe some minimum performance characteristics that we need to be able to see such as sensitivity and specificity. And an example is if specificity is not high enough, we would want to understand why that is. And perhaps more cross-reactivity testing with known potential cross-reacting respiratory pathogens may be required to understand the performance of that test.
SPEAKER QUESTION: Julie Leslie
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care testing data requirements, Sensitivity and specificity for testing, Cross-reactivity testing
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: What is needed to demonstrate the equivalency of a fingerstick sample and other evaluated sample types for point-of-care tests?
CLARIFIED ANSWER: FDA requires data demonstrating that accurate testing can be performed in point-of-care settings by non-laboratory professionals. For fingerstick samples, data must prove equivalency with another evaluated sample type, meeting minimum performance standards like sensitivity and specificity.
VERBATIM QUESTION: What is needed to demonstrate the equivalency of a fingerstick sample and other evaluated sample types for point-of-care tests?
VERBATIM ANSWER: we want to see the data that accurate testing can be performed in the point of care testing site in a wave setting with users that are not trained laboratory professionals. And if fingerstick is an important element of that point of care setting, to be able to see data show the equivalency for that particular test between point of care - I mean fingerstick and another sample type that's also been evaluated. So we think this is possible. Our template will describe some minimum performance characteristics that we need to be able to see such as sensitivity and specificity.
SPEAKER QUESTION: Julie Leslie
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: fingerstick sample equivalency, point-of-care tests, sensitivity and specificity
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: What are the minimum performance characteristics required in the FDA template for authorizing point-of-care tests?
CLARIFIED ANSWER: FDA requires point-of-care tests to demonstrate accurate testing by untrained users, equivalency between sample types, and minimum performance characteristics such as sensitivity and specificity. Additional cross-reactive testing or confirmation with higher-quality tests may be needed.
VERBATIM QUESTION: What are the minimum performance characteristics required in the FDA template for authorizing point-of-care tests?
VERBATIM ANSWER: So we are very interested in authorizing point-of-care tests -- both molecular and serology. As I said in response to the last question, we want to see the data that accurate testing can be performed in the point of care testing site in a wave setting with users that are not trained laboratory professionals. And if fingerstick is an important element of that point of care setting, to be able to see data show the equivalency for that particular test between point of care - I mean fingerstick and another sample type that's also been evaluated. So we think this is possible. Our template will describe some minimum performance characteristics that we need to be able to see such as sensitivity and specificity. And an example is if specificity is not high enough, we would want to understand why that is. And perhaps more cross-reactivity testing with known potential cross-reacting respiratory pathogens may be required to understand the performance of that test. As I said in my introductory remarks though, even if you have a very highly specific test - one of these very high-quality, high-throughput central lab tests which have studied over 1000 patients - the lower end of the confidence interval at 99% in certain populations may not be alone high enough to make important clinical decisions for that patient. And confirmatory serology testing may the important element serology testing -- making a decision based on even a high-performing test may not be sufficient to ensure that you know what really happened with that patient. Hopefully, that addresses your FDA question. I would also add that performance at the point of care potentially could be a little bit lower as long as it's reflexed for confirmation to a higher-performing central lab test.
SPEAKER QUESTION: Julie Leslie
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA templates, performance criteria, point-of-care tests
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: How should developers address low specificity in their serology tests, and what cross-reactivity testing may be required?
CLARIFIED ANSWER: FDA suggests understanding the cause of low specificity in serology tests and conducting additional cross-reactivity testing with known potential cross-reacting respiratory pathogens to evaluate test performance.
VERBATIM QUESTION: How should developers address low specificity in their serology tests, and what cross-reactivity testing may be required?
VERBATIM ANSWER: Our template will describe some minimum performance characteristics that we need to be able to see such as sensitivity and specificity. And an example is if specificity is not high enough, we would want to understand why that is. And perhaps more cross-reactivity testing with known potential cross-reacting respiratory pathogens may be required to understand the performance of that test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test specificity, Cross-reactivity testing, Performance evaluation
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: Why might even highly specific serology tests require confirmatory testing for clinical decision-making?
CLARIFIED ANSWER: Even a highly specific serology test with a 99% confidence interval may not provide sufficient certainty for clinical decision-making in certain populations, making confirmatory testing essential.
VERBATIM QUESTION: Why might even highly specific serology tests require confirmatory testing for clinical decision-making?
VERBATIM ANSWER: As I said in my introductory remarks though, even if you have a very highly specific test - one of these very high-quality, high-throughput central lab tests which have studied over 1000 patients - the lower end of the confidence interval at 99% in certain populations may not be alone high enough to make important clinical decisions for that patient. And confirmatory serology testing may the important element serology testing -- making a decision based on even a high-performing test may not be sufficient to ensure that you know what really happened with that patient.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test validation, specificity and confirmation
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: Under what conditions might the FDA accept slightly lower performance for point-of-care tests if they are paired with confirmatory central lab testing?
CLARIFIED ANSWER: The FDA may accept slightly lower performance for point-of-care tests if they are paired with confirmatory testing from higher-performing central lab tests.
VERBATIM QUESTION: Under what conditions might the FDA accept slightly lower performance for point-of-care tests if they are paired with confirmatory central lab testing?
VERBATIM ANSWER: I would also add that performance at the point of care potentially could be a little bit lower as long as it's reflexed for confirmation to a higher-performing central lab test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: point-of-care test performance, confirmatory testing, FDA test requirements
REVIEW FLAG: False


#### 5. Verification Challenges and Neutralizing Antibody Testing Insights

QA Block 5-1
CLARIFIED QUESTION: How can labs verify the Abbott ID Now test if they can only use a direct swab method, given that instructions for this are not in the package insert?
CLARIFIED ANSWER: Labs can contrive samples from known positive patient samples, dilute them to low positive levels, and apply them onto swabs to verify Abbott ID Now test performance without needing direct patient swabs.
VERBATIM QUESTION: How can labs verify the Abbott ID Now test if they can only use a direct swab method, given that instructions for this are not in the package insert?
VERBATIM ANSWER: Yes. So you could contrive samples in the lab to verify testing. So take a known positive patient sample from VTM, understand, you know, where the range of positivity is if you have a molecular test that gives you cycle thresholds. Find something near, you know, a low positive or dilute it down to a low positive. You can then pipe that on to swabs in replicates and test that in the Abbott ID Now. That would be one possible way to verify performance of the Abbott ID Now in your hands without having to go ahead and actually swab patients and swab enough patients that you get a positive patient to compare.
SPEAKER QUESTION: Cynthia Flynn
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Abbott ID Now test verification, Direct swab method, VTM recall
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: Are you going to conduct plaque studies during serology studies to evaluate whether true neutralizing antibodies are detected?
CLARIFIED ANSWER: The FDA is in early discussions with developers regarding neutralizing antibody tests, which are challenging to perform. Such tests could help determine adaptive immune responses but don't always link antibodies to immunity or infection-fighting ability.
VERBATIM QUESTION: Are you going to conduct plaque studies during serology studies to evaluate whether true neutralizing antibodies are detected?
VERBATIM ANSWER: Yes. I mean if you're really wanting to understand is the adaptive immune response producing antibodies that can fight the infection, you would want to know whether or not neutralizing antibodies are present. And for those clinicians who are looking at potentially using convalescent plasma to treat patients, you would also want to know are neutralizing antibodies present. So we are in early dialogue with some developers of neutralizing antibody test. That is not something that's usually performed. And it would be, you know, and sort of uneasy to perform tests. So we hope to see more developers of assays that can measure neutralizing antibodies. And that would be very informative. We do have the ability in some cases with some developers to try to correlate detection of antibodies and also in the same samples realize whether or not those samples have neutralizing antibodies. But unfortunately, it's not always clear that all the antibodies in the adaptive immune response are going to be neutralizing. So it's a bit of a challenge for the tests that aren't designed to measure specifically neutralizing antibodies to be able to make any sort of determination. So we believe it's important that it's clear that although some of these serology tests can accurately measure the presence of antibodies that arise to the infection, that it doesn't equate with immunity or the ability to fight off an infection.
SPEAKER QUESTION: Cynthia Flynn
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Neutralizing antibodies, Serology studies, Immunity testing
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: Can positive patient samples in VTM be diluted to create low positive controls for validation of the Abbott ID Now test?
CLARIFIED ANSWER: Positive patient samples in VTM can be diluted to create low positive controls and used to validate Abbott ID Now by pipetting them onto swabs in replicates for testing.
VERBATIM QUESTION: Can positive patient samples in VTM be diluted to create low positive controls for validation of the Abbott ID Now test?
VERBATIM ANSWER: Yes. So you could contrive samples in the lab to verify testing. So take a known positive patient sample from VTM, understand, you know, where the range of positivity is if you have a molecular test that gives you cycle thresholds. Find something near, you know, a low positive or dilute it down to a low positive. You can then pipe that on to swabs in replicates and test that in the Abbott ID Now. That would be one possible way to verify performance of the Abbott ID Now in your hands with not having to go ahead and actually swab patients and swab enough patients that you get a positive patient to compare.
SPEAKER QUESTION: Cynthia Flynn
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Abbott ID Now, VTM dilution for validation, Low positive control creation
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: How can interfering substances present in nasal swabs be tested when verifying the Abbott ID Now test?
CLARIFIED ANSWER: To test for potential interfering substances in nasal swabs when verifying the Abbott ID Now test, one could dilute a sample into a negative specimen for evaluation.
VERBATIM QUESTION: How can interfering substances present in nasal swabs be tested when verifying the Abbott ID Now test?
VERBATIM ANSWER: ...so that you also test potential interfering substances that are present in the nasal swab.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Interfering substances, Abbott ID Now test, Verification process
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: Is there a recommended approach to correlating neutralizing antibodies with total antibody detection in serology tests?
CLARIFIED ANSWER: FDA acknowledges that correlating neutralizing antibodies with total antibodies is challenging. They are in discussions with developers for neutralizing antibody tests, which could help measure the adaptive immune response more accurately. However, many serology tests do not directly measure neutralizing antibodies, and testing doesn't equate to immunity.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Yes. I mean if you're really wanting to understand is the adaptive immune response producing antibodies that can fight the infection, you would want to know whether or not neutralizing antibodies are present. And for those clinicians who are looking at potentially using convalescent plasma to treat patients, you would also want to know are neutralizing antibodies present. So we are an early dialogue with some developers of neutralizing antibody test. That is not something that's usually performed. And it would be, you know, and sort of uneasy to perform tests. So we hope to see more developers of assays that can measure neutralizing antibodies. And that would be very informative. We do have the ability in some cases with some developers to try to correlate detection of antibodies and also in the same samples realize whether or not those samples have neutralizing antibodies. But unfortunately, it's not always clear that all the antibodies in the adaptive immune response are going to be neutralizing. So it's a bit of a challenge for the tests that aren't designed to measure specifically neutralizing antibodies to be able to make any sort of determination. So we believe it's important that it's clear that although some of these serology tests can accurately measure the presence of antibodies that arise to the infection, that it doesn't equate with immunity or the ability to fight off an infection.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: neutralizing antibodies, serology test limitations, test development
REVIEW FLAG: False

QA Block 5-7
CLARIFIED QUESTION: What challenges exist in designing tests to specifically measure neutralizing antibodies?
CLARIFIED ANSWER: Tests designed to measure neutralizing antibodies face challenges because not all antibodies in the immune response are neutralizing, making it unclear if detection equates to immunity.
VERBATIM QUESTION: What challenges exist in designing tests to specifically measure neutralizing antibodies?
VERBATIM ANSWER: And it would be, you know, and sort of uneasy to perform tests. So we hope to see more developers of assays that can measure neutralizing antibodies. And that would be very informative. We do have the ability in some cases with some developers to try to correlate... detection of antibodies and also in the same samples realize whether or not those samples have neutralizing antibodies. But unfortunately, it's not always clear that all the antibodies in the adaptive immune response are going to be neutralizing. So it's a bit of a challenge for the tests that aren't designed to measure specifically neutralizing antibodies to be able to make any sort of determination.
SPEAKER QUESTION: Cynthia Flynn
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Neutralizing antibodies, Challenges in test design, Immunity and serology
REVIEW FLAG: False

QA Block 5-8
CLARIFIED QUESTION: Why doesn't the detection of antibodies through serology tests equate to confirmed immunity against infection?
CLARIFIED ANSWER: The FDA clarified that detecting antibodies through serology tests does not necessarily indicate immunity or the ability to combat the infection.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: So we believe it's important that it's clear that although some of these serology tests can accurately measure the presence of antibodies that arise to the infection, that it doesn't equate with immunity or the ability to fight off an infection.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antibody detection in serology tests, Immunity confirmation, COVID-19 diagnostics
REVIEW FLAG: False


#### 6. Progress on Rapid Antigen Test Development and Comparisons

QA Block 6-1
CLARIFIED QUESTION: What is the progress on the FDA template for rapid viral detection immunoassays?
CLARIFIED ANSWER: The FDA has made significant progress on the template for rapid viral detection immunoassays. After completing the serology templates, the next focus will be rapid antigen tests, and developers are encouraged to engage with the FDA. The FDA has experience with similar tests for respiratory pathogens and recognizes the potential of anterior nares samples for these tests.
VERBATIM QUESTION: What is the progress on the FDA template for rapid viral detection immunoassays?
VERBATIM ANSWER: Yes. We've made significant progress. And it's the priority as soon as we get the serology templates out is the next priority is the rapid antigen tests. And we invite all developers to come and dialogue with us. We obviously have authorized quite a few rapid antigen tests for other respiratory pathogens and so have a relatively good understanding. We also know that the anterior nares may harbor enough virus to make these rapid antigen tests plausible. It would be ideal if they were on performance par with the new standards for say flu detection with rapid tests.
SPEAKER QUESTION: Arianna Hawkins
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA template for immunoassays, rapid antigen tests, development progress
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: Are there any concerns about detection and comparison using molecular tests as the comparator method?
CLARIFIED ANSWER: FDA recommends comparing rapid SARS-CoV-2 antigen test performance to molecular assays, as it is an excellent benchmark.
VERBATIM QUESTION: Are there any concerns about detection and comparison using molecular tests as the comparator method?
VERBATIM ANSWER: I think Labs who are interested in and other healthcare professionals that are interested in acquiring rapid SARS-CoV-2 rapid antigen tests are going to want to know what is the performance relative to molecular assays. So that is probably an excellent performance comparison to do.
SPEAKER QUESTION: Arianna Hawkins
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: rapid antigen test comparison, molecular assays, test performance
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: What is the expected performance standard for rapid antigen tests compared to molecular assays?
CLARIFIED ANSWER: FDA considers performance comparison of rapid antigen tests to molecular assays, which are more sensitive, as an excellent standard for evaluation.
VERBATIM QUESTION: What is the expected performance standard for rapid antigen tests compared to molecular assays?
VERBATIM ANSWER: I think Labs who are interested in and other healthcare professionals that are interested in acquiring rapid SARS-CoV-2 rapid antigen tests are going to want to know what is the performance relative to molecular assays. So that is probably an excellent performance comparison to do.
SPEAKER QUESTION: Arianna Hawkins
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: performance standards, rapid antigen tests, molecular assay comparison
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: Does the FDA have specific recommendations for using anterior nares samples in rapid antigen testing?
CLARIFIED ANSWER: The FDA considers anterior nares samples to harbor enough virus for rapid antigen tests to be feasible and suggests they ideally meet performance standards similar to flu rapid tests.
VERBATIM QUESTION: Does the FDA have specific recommendations for using anterior nares samples in rapid antigen testing?
VERBATIM ANSWER: We also know that the anterior nares may harbor enough virus to make these rapid antigen tests plausible. It would be ideal if they were on performance par with the new standards for say flu detection with rapid tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: anterior nares samples, rapid antigen tests, performance standards
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: Should the performance of rapid antigen tests be benchmarked against existing standards for flu detection?
CLARIFIED ANSWER: The FDA states that it would be ideal for rapid antigen tests to perform comparably to new standards for flu detection.
VERBATIM QUESTION: Should the performance of rapid antigen tests be benchmarked against existing standards for flu detection?
VERBATIM ANSWER: It would be ideal if they were on performance par with the new standards for say flu detection with rapid tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: rapid antigen test performance, standards for flu detection
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: What is the FDA's perspective on rapid antigen tests' plausibility based on anterior nares viral load?
CLARIFIED ANSWER: The FDA believes that the anterior nares may hold sufficient viral load to make rapid antigen tests feasible, ideally achieving performance comparable to new rapid flu detection standards.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We also know that the anterior nares may harbor enough virus to make these rapid antigen tests plausible. It would be ideal if they were on performance par with the new standards for say flu detection with rapid tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: rapid antigen tests, anterior nares viral load, test performance standards
REVIEW FLAG: False

QA Block 6-7
CLARIFIED QUESTION: What specific criteria should labs or healthcare professionals consider when evaluating rapid antigen test performance?
CLARIFIED ANSWER: FDA recommends comparing the performance of rapid antigen tests to molecular assays, such as PCR tests, to evaluate their efficacy.
VERBATIM QUESTION: What specific criteria should labs or healthcare professionals consider when evaluating rapid antigen test performance?
VERBATIM ANSWER: I think Labs who are interested in and other healthcare professionals that are interested in acquiring rapid SARS-CoV-2 rapid antigen tests are going to want to know what is the performance relative to molecular assays.
SPEAKER QUESTION: Arianna Hawkins
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: rapid antigen test performance, comparison to molecular assays
REVIEW FLAG: False


#### 7. Home Use Usability Testing for Diagnostic Products

QA Block 7-1
CLARIFIED QUESTION: Would it be helpful if we prepared a template for home use serology testing?
CLARIFIED ANSWER: The FDA welcomes assistance with a template for home use serology testing. While they can't guarantee its incorporation, they encourage sending ideas to the CDRH-EUA-templates@fda.hhs.gov email address for review.
VERBATIM QUESTION: Would it be helpful if we prepared a template for home use serology testing?
VERBATIM ANSWER: We would love assistance. We can't promise that we'll incorporate the idea but you certainly can send your ideas into our CDRH-EUA- templates@fda.hhs.gov email address and we will take a look at it.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home use serology testing, FDA template submission
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: For the home usability testing for pixel, can you share whether you required 15 laypeople for the study?
CLARIFIED ANSWER: FDA conducted simulated home-use testing with individuals inexperienced with nasal swab collection, assessing sampling adequacy and utilizing internal controls to ensure the adequacy of the obtained samples.
VERBATIM QUESTION: For the home usability testing for pixel, can you share whether you required 15 laypeople for the study?
VERBATIM ANSWER: So it was a simulated home use testing sort of environment with folks inexperienced with collecting a nasal swab on themselves given only the directions in the kit to perform. And we were able to assess adequate sampling in these situations important features of an assay that utilize such home or self-collection is that there are internal controls that are able to assess whether the sample is adequate they obtained.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home usability testing, simulated testing environment, internal controls
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: Was the pixel study a clinical home usability study with clinical endpoints or just a pure usability study with no clinical endpoint?
CLARIFIED ANSWER: The pixel study was a simulated home use testing environment with inexperienced participants collecting nasal swabs using kit directions. Internal controls were used to assess sample adequacy.
VERBATIM QUESTION: Was the pixel study a clinical home usability study with clinical endpoints or just a pure usability study with no clinical endpoint?
VERBATIM ANSWER: So it was a simulated home use testing sort of environment with folks inexperienced with collecting a nasal swab on themselves given only the directions in the kit to perform. And we were able to assess adequate sampling in these situations important features of an assay that utilize such home or self-collection is that there are internal controls that are able to assess whether the sample is adequate they obtained.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home use testing, clinical vs. usability study, sample adequacy
REVIEW FLAG: False


#### 8. Guidelines for Antibody Test Validation and Approvals

QA Block 8-1
CLARIFIED QUESTION: Is it acceptable to use only five out of the recommended seven samples for cross-reactivity testing for an IgM and IgG antibody test?
CLARIFIED ANSWER: The FDA suggests alternate methods for cross-reactivity assessment if you can't obtain all recommended samples. Using a variety of negative samples, including recent pre-COVID-19 exposures, is an acceptable surrogate approach. More final guidance will be available in the FDA template.
VERBATIM QUESTION: Is it acceptable to use only five out of the recommended seven samples for cross-reactivity testing for an IgM and IgG antibody test?
VERBATIM ANSWER: So our template -- which hopefully will come out very soon -- explain the number of these situations. In the interim, you can engage with our expert FDA staff through the template email. But in general, there are alternate ways to achieve adequate assessment of cross-reactivity. For example, obviously the more known samples with known convalescent plasma or serum that you have that's specific to certain respiratory viruses is helpful in our assessment. However, you can test a minimum number of negatives -- a variety of negatives -- some of which, many of which can be pre-COVID-19 but not too old. We want to see folks that have been exposed recently to a variety of respiratory pathogens. And so by simply assessing you know, enough negative patients you can get a surrogate assessment of potential cross-reactivity -- especially as it relates to the general population. So that is an alternate way to do that. And the template will layout minimum numbers which I don't want to speak FDA to right now because they haven't been totally cleared for representing that publicly. But we will post it on our website as soon as it is cleared. And in the interim, you can get those numbers from our staff. So there are two alternate ways of going at that.
SPEAKER QUESTION: Carney
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: cross-reactivity testing, IgM/IgG antibody tests, FDA guidance
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: How can we demonstrate that our test can detect both IgG and IgM antibodies?
CLARIFIED ANSWER: The FDA suggests that to demonstrate class specificity, well-characterized anti-IgG and anti-IgM antibodies can be used, along with evidence from previous studies. Chemical methods may also be employed, both of which will be detailed in an upcoming template.
VERBATIM QUESTION: Can you explain more on how we can demonstrate that our test can detect IgG and IgM both?
VERBATIM ANSWER: And as far as class specificity goes, our template will also outline multiple methods to achieve it. One is you may have well-characterized anti-IgG, anti-IgM antibodies for the detection. And so if those antibodies are well characterized for other potential uses that you have used them for, those previous studies can be used does evidence. There are also chemical ways of achieving this is well and those will be outlined in the template that are you now waiting for final clearance.
SPEAKER QUESTION: Carney
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: class specificity, detecting antibodies, FDA guidance
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: Can we use the FDA template for validation even if our current validation is incorrect?
CLARIFIED ANSWER: FDA allows developers to notify completed validations using pathways C or D. If applying for EUA, FDA reviews the data for risks of inaccuracies and can permit market presence while requiring additional studies, if needed.
VERBATIM QUESTION: Can we use the FDA template for validation even if our current validation is incorrect?
VERBATIM ANSWER: So through pathway C or D, developers can let us know that they have completed validation and launch. If you're interested in an EUAauthorization we when we receive the EUA package we will take a look at the acceptability of the studies and the study designs that you performed. If there are no outward signs of risk to inaccurate results, we will work with you and allow developers to stay in the market while we assess potential additional studies. So that's our general way of handling things for years and years here in similar situations.
SPEAKER QUESTION: Carney
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA template use, Validation review, EUA process
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: What are the minimum acceptable numbers of samples needed for cross-reactivity testing if seven cannot be acquired?
CLARIFIED ANSWER: Alternative methods to assess cross-reactivity include testing a variety of negative samples, ideally from individuals recently exposed to respiratory pathogens. Official minimum sample numbers will be posted on the FDA website or are available from FDA staff.
VERBATIM QUESTION: What are the minimum acceptable numbers of samples needed for cross-reactivity testing if seven cannot be acquired?
VERBATIM ANSWER: Our template -- which hopefully will come out very soon -- explain the number of these situations. In the interim, you can engage with our expert FDA staff through the template email. But in general, there are alternate ways to achieve adequate assessment of cross-reactivity. For example, obviously the more known samples with known convalescent plasma or serum that you have that's specific to certain respiratory viruses is helpful in our assessment. However, you can test a minimum number of negatives -- a variety of negatives -- some of which, many of which can be pre-COVID-19 but not too old. We want to see folks that have been exposed recently to a variety of respiratory pathogens. And so by simply assessing you know, enough negative patients you can get a surrogate assessment of potential cross-reactivity -- especially as it relates to the general population. So that is an alternate way to do that. And the template will layout minimum numbers which I don't want to speak FDA to right now because they haven't been totally cleared for representing that publicly. But we will post it on our website as soon as it is cleared. And in the interim, you can get those numbers from our staff.
SPEAKER QUESTION: Carney
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Cross-reactivity testing, Sample requirements, FDA guidance
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: Are pre-COVID-19 samples acceptable for cross-reactivity testing, and are there limitations on their use?
CLARIFIED ANSWER: Pre-COVID-19 samples are acceptable for cross-reactivity testing as long as they are not too old and reflect recent exposure to various respiratory pathogens. Testing enough negative samples can serve as a surrogate assessment for cross-reactivity.
VERBATIM QUESTION: Are pre-COVID-19 samples acceptable for cross-reactivity testing, and are there limitations on their use?
VERBATIM ANSWER: In the interim, you can engage with our expert FDA staff through the template email. But in general, there are alternate ways to achieve adequate assessment of cross-reactivity. For example, obviously the more known samples with known convalescent plasma or serum that you have that's specific to certain respiratory viruses is helpful in our assessment. However, you can test a minimum number of negatives -- a variety of negatives -- some of which, many of which can be pre-COVID-19 but not too old. We want to see folks that have been exposed recently to a variety of respiratory pathogens. And so by simply assessing you know, enough negative patients you can get a surrogate assessment of potential cross-reactivity -- especially as it relates to the general population. So that is an alternate way to do that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Cross-reactivity testing, Use of pre-COVID-19 samples
REVIEW FLAG: False

QA Block 8-6
CLARIFIED QUESTION: What constitutes recent exposure to respiratory pathogens when selecting negative samples for cross-reactivity testing?
CLARIFIED ANSWER: Recent exposure to respiratory pathogens refers to individuals who have been in contact with various respiratory pathogens not too long ago to ensure representative negative samples for cross-reactivity testing.
VERBATIM QUESTION: What constitutes recent exposure to respiratory pathogens when selecting negative samples for cross-reactivity testing?
VERBATIM ANSWER: We want to see folks that have been exposed recently to a variety of respiratory pathogens. And so by simply assessing you know, enough negative patients you can get a surrogate assessment of potential cross-reactivity -- especially as it relates to the general population.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Cross-reactivity testing, Negative sample selection
REVIEW FLAG: False

QA Block 8-7
CLARIFIED QUESTION: Can prior studies using well-characterized antibodies be reused to demonstrate class specificity?
CLARIFIED ANSWER: The FDA allows prior studies with well-characterized anti-IgG and anti-IgM antibodies to be used as evidence to demonstrate class specificity. Additional methods, including chemical approaches, will be provided in the forthcoming template.
VERBATIM QUESTION: Can prior studies using well-characterized antibodies be reused to demonstrate class specificity?
VERBATIM ANSWER: Our template will also outline multiple methods to achieve it. One is you may have well-characterized anti-IgG, anti-IgM antibodies for the detection. And so if those antibodies are well characterized for other potential uses that you have used them for, those previous studies can be used does [as] evidence. There are also chemical ways of achieving this is well and those will be outlined in the template that are you now waiting for final clearance.
SPEAKER QUESTION: Carney
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: class specificity, antibody reuse, FDA testing templates
REVIEW FLAG: False

QA Block 8-8
CLARIFIED QUESTION: Does the FDA provide a specific list of acceptable chemical methods for demonstrating class specificity?
CLARIFIED ANSWER: The FDA template will outline multiple acceptable methods for achieving class specificity, including chemical methods, but it is still awaiting final clearance.
VERBATIM QUESTION: Does the FDA provide a specific list of acceptable chemical methods for demonstrating class specificity?
VERBATIM ANSWER: Our template will also outline multiple methods to achieve it. One is you may have well-characterized anti-IgG, anti-IgM antibodies for the detection. And so if those antibodies are well characterized for other potential uses that you have used them for, those previous studies can be used does evidence. There are also chemical ways of achieving this is well and those will be outlined in the template that are you now waiting for final clearance.
SPEAKER QUESTION: Carney
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: class specificity methods, FDA template
REVIEW FLAG: False

QA Block 8-9
CLARIFIED QUESTION: What steps should a developer take if validation is completed, but their study designs do not fully meet the FDA's expectations?
CLARIFIED ANSWER: Developers can notify the FDA through pathway C or D after completing validation and launching their tests. If they seek EUA, the FDA will review their studies and, unless there are clear risks of inaccurate results, allow them to remain on the market while any additional assessments are conducted.
VERBATIM QUESTION: What steps should a developer take if validation is completed, but their study designs do not fully meet the FDA's expectations?
VERBATIM ANSWER: So through pathway C or D, developers can let us know that they have completed validation and launch. If you're interested in an EUAauthorization we when we receive the EUA package we will take a look at the acceptability of the studies and the study designs that you performed. If there are no outward signs of risk to inaccurate results, we will work with you and allow developers to stay in the market while we assess potential additional studies. So that's our general way of handling things for years and years here in similar situations.
SPEAKER QUESTION: Carney
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation process, EUA submission, Study design completion
REVIEW FLAG: False

QA Block 8-10
CLARIFIED QUESTION: Can a test remain on the market after validation if inaccuracies are identified during FDA review?
CLARIFIED ANSWER: FDA allows tests to remain on the market after validation if there are no evident risks of inaccurate results, even as the agency works with developers to assess and address additional study needs.
VERBATIM QUESTION: Can a test remain on the market after validation if inaccuracies are identified during FDA review?
VERBATIM ANSWER: So through pathway C or D, developers can let us know that they have completed validation and launch. If you're interested in an EUAauthorization we when we receive the EUA package we will take a look at the acceptability of the studies and the study designs that you performed. If there are no outward signs of risk to inaccurate results, we will work with you and allow developers to stay in the market while we assess potential additional studies. So that's our general way of handling things for years and years here in similar situations.
SPEAKER QUESTION: Carney
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test validation, FDA review process, market eligibility
REVIEW FLAG: False


#### 9. CLIA Complexity Determination Process Under Emergency Use Authorization

QA Block 9-1
CLARIFIED QUESTION: If you have an EUA, would you be cleared for non-CLIA laboratories to use?
CLARIFIED ANSWER: Tests authorized under EUA are generally categorized as high complexity, but in emergencies, the FDA can deem them as moderately complex or waived. Such designations are communicated in authorization letters and on the FDA website.
VERBATIM QUESTION: If you have an EUA, would you be cleared for non-CLIA laboratories to use?
VERBATIM ANSWER: Yes. So first of all, those developers that notify us through pathway C or D are automatically put into a high complexity category. And that should be those that we have listed already, those should be designated on our FAQ page now in such a manner as H for high complexity. As soon as we're able to authorize them and if we authorize them for moderate complexity situations and/or waved situations, the website authorization will be updated with that information and the website will be updated as well. So we take a traditional approach on assessing whether a technology is acceptable for other than a high-complexity environment -- whether it can be moderately complex or a wave setting. We do not do a formal complexity determination as we could do outside of an emergency situation. Our office at the FDA is legally responsible for making those assessments for CLIA categorization. That task has been assigned to our office and we have staff who are experienced in that. FDA In the emergency use situation, we are allowed under law to deem a test as moderately complex and/or waved. It is not a formal classification. We make that deemed status clear in our authorization letter and in a language that's allowed in the developer's instructions for use. And we'll make that publicly available clearly on our website as well.
SPEAKER QUESTION: Michael Ross
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorization, CLIA laboratory use, FDA categorization process
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: Since the FDA doesn't control CLIA, what is the mechanism for using tests in non-CLIA laboratories?
CLARIFIED ANSWER: FDA places tests notified via certain pathways into the high-complexity category and updates complexity classifications for non-high complexity situations on its website. During emergencies, FDA legally deems tests as moderate complexity or waived in the EUA authorization and public materials, bypassing formal CLIA classification processes.
VERBATIM QUESTION: Since the FDA doesn't control CLIA, what is the mechanism for using tests in non-CLIA laboratories?
VERBATIM ANSWER: Yes. So first of all, those developers that notify us through pathway C or D are automatically put into a high complexity category. And that should be those that we have listed already, those should be designated on our FAQ page now in such a manner as H for high complexity. As soon as we're able to authorize them and if we authorize them for moderate complexity situations and/or waved situations, the website authorization will be updated with that information and the website will be updated as well. So we take a traditional approach on assessing whether a technology is acceptable for other than a high-complexity environment -- whether it can be moderately complex or a wave setting. We do not do a formal complexity determination as we could do outside of an emergency situation. Our office at the FDA is legally responsible for making those assessments for CLIA categorization. That task has been assigned to our office and we have staff who are experienced in that. FDA In the emergency use situation, we are allowed under law to deem a test as moderately complex and/or waved. It is not a formal classification. We make that deemed status clear in our authorization letter and in a language that's allowed in the developer's instructions for use. And we'll make that publicly available clearly on our website as well.
SPEAKER QUESTION: Michael Ross
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA and CLIA regulation, Test complexity categorization, Emergency use authorizations
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: What does the FDA mean by "pathway C or D," and how do developers notify the FDA through these pathways?
CLARIFIED ANSWER: Developers notifying the FDA through pathway C or D are placed in a high complexity category, noted with H for high complexity on the FAQ page. Upon authorization for moderate complexity or waived use, the FDA updates the authorization and website accordingly.
VERBATIM QUESTION: What does the FDA mean by "pathway C or D," and how do developers notify the FDA through these pathways?
VERBATIM ANSWER: So first of all, those developers that notify us through pathway C or D are automatically put into a high complexity category. And that should be those that we have listed already, those should be designated on our FAQ page now in such a manner as H for high complexity. As soon as we're able to authorize them and if we authorize them for moderate complexity situations and/or waved situations, the website authorization will be updated with that information and the website will be updated as well. So we take a traditional approach on assessing whether a technology is acceptable for other than a high-complexity environment -- whether it can be moderately complex or a wave setting.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pathway C or D, FDA complexity categorization, EUA updates
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: What criteria does the FDA use to assess whether a test is suitable for moderate complexity or waived settings?
CLARIFIED ANSWER: The FDA assesses whether a test can be designated for moderate complexity or waived settings through a traditional assessment of the technology's suitability. Tests are initially categorized as high complexity, and updates are made if deemed suitable for other categories. Formal complexity determinations are not performed under EUA, but the FDA deems a test's status and makes it clear in authorization letters and on its website.
VERBATIM QUESTION: What criteria does the FDA use to assess whether a test is suitable for moderate complexity or waived settings?
VERBATIM ANSWER: So first of all, those developers that notify us through pathway C or D are automatically put into a high complexity category. And that should be those that we have listed already, those should be designated on our FAQ page now in such a manner as H for high complexity. As soon as we're able to authorize them and if we authorize them for moderate complexity situations and/or waved situations, the website authorization will be updated with that information and the website will be updated as well. So we take a traditional approach on assessing whether a technology is acceptable for other than a high-complexity environment -- whether it can be moderately complex or a wave setting. We do not do a formal complexity determination as we could do outside of an emergency situation. Our office at the FDA is legally responsible for making those assessments for CLIA categorization. That task has been assigned to our office and we have staff who are experienced in that. FDA In the emergency use situation, we are allowed under law to deem a test as moderately complex and/or waved. It is not a formal classification. We make that deemed status clear in our authorization letter and in a language that's allowed in the developer's instructions for use. And we'll make that publicly available clearly on our website as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Complexity categorization, FDA criteria, CLIA settings
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: How does the FDA determine and assign deemed status for test complexity during an emergency use situation?
CLARIFIED ANSWER: The FDA uses an expedited process during emergencies to assign deemed complexity for diagnostic tests. Tests from developers notifying under pathways C or D are automatically high complexity. For moderate complexity or waived situations, the FDA evaluates the technology and updates its authorization and website. This process is not a formal classification but deemed status is made clear in authorization letters and instructions for use.
VERBATIM QUESTION: How does the FDA determine and assign deemed status for test complexity during an emergency use situation?
VERBATIM ANSWER: Yes. So first of all, those developers that notify us through pathway C or D are automatically put into a high complexity category. And that should be those that we have listed already, those should be designated on our FAQ page now in such a manner as H for high complexity. As soon as we're able to authorize them and if we authorize them for moderate complexity situations and/or waved situations, the website authorization will be updated with that information and the website will be updated as well. So we take a traditional approach on assessing whether a technology is acceptable for other than a high-complexity environment -- whether it can be moderately complex or a wave setting. We do not do a formal complexity determination as we could do outside of an emergency situation. Our office at the FDA is legally responsible for making those assessments for CLIA categorization. That task has been assigned to our office and we have staff who are experienced in that. FDA In the emergency use situation, we are allowed under law to deem a test as moderately complex and/or waved. It is not a formal classification. We make that deemed status clear in our authorization letter and in a language that's allowed in the developer's instructions for use. And we'll make that publicly available clearly on our website as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA categorization, Test complexity, Emergency use authorization
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: What information does the FDA include in its authorization letters regarding test complexity determinations?
CLARIFIED ANSWER: FDA includes the deemed complexity status (moderately complex and/or waived) in its authorization letters and in the developer's instructions for use. This information is also made publicly available on their website.
VERBATIM QUESTION: What information does the FDA include in its authorization letters regarding test complexity determinations?
VERBATIM ANSWER: In the emergency use situation, we are allowed under law to deem a test as moderately complex and/or waved. It is not a formal classification. We make that deemed status clear in our authorization letter and in a language that's allowed in the developer's instructions for use. And we'll make that publicly available clearly on our website as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA test complexity, authorization letters, public communication
REVIEW FLAG: False

QA Block 9-7
CLARIFIED QUESTION: Where on the FDA's website can developers find the updated complexity categorizations of authorized tests?
CLARIFIED ANSWER: Developers can find the updated complexity categorizations of authorized tests, including high complexity (denoted as H), on the FDA FAQ page, and these are updated upon additional authorizations.
VERBATIM QUESTION: Where on the FDA's website can developers find the updated complexity categorizations of authorized tests?
VERBATIM ANSWER: Those developers that notify us through pathway C or D are automatically put into a high complexity category. And that should be those that we have listed already, those should be designated on our FAQ page now in such a manner as H for high complexity. As soon as we're able to authorize them and if we authorize them for moderate complexity situations and/or waved situations, the website authorization will be updated with that information and the website will be updated as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test complexity categorization, FDA FAQ page, authorization updates
REVIEW FLAG: False


#### 10. Saliva Sample Validation Requirements for COVID-19 Diagnostics

QA Block 10-1
CLARIFIED QUESTION: Does the FDA require a EUA submission if a high-complexity lab using a FDA-approved EUA molecular test for respiratory specimens wants to validate and use saliva as a sample type?
CLARIFIED ANSWER: FDA requests developers validating saliva as a sample type to discuss their design and data sufficiency with the FDA. Saliva presents challenges, and data from its use has often been inadequate. This process ensures validation safety until its performance can be better defined.
VERBATIM QUESTION: Okay. So if you're a high-complexity lab using an FDA approved EUA molecular test that's authorized for respiratory specimens, does FDA require a EUA submission if that lab wants to validate and use saliva as a sample type? Or can they perform that validation under their CLIA license?
VERBATIM ANSWER: Yes. So that frequently involves a collection device that is not formally covered under you know, the COVID-19 diagnostic situation. We have also seen data from saliva that is not really good enough for clinical use. So we are currently asking developers who want to utilize saliva -- and we do encourage it because we obviously already authorized one such test -- to come in and discuss their design with us and make sure that whatever data is generated it's FDA going to be sufficient for us to say yes, that looks good. And, you know, until such a time that we can define the true performance of saliva and we can predict the performance, we think this is the safest way to go right now. And there is - some of the data is just not good enough to support it and we don't know all the variables such as how do you need to preserve it, how do you store it, how do you transport it, and how do you extract it. And then what particular tests perform well on saliva-based samples.
SPEAKER QUESTION: Karen Richards
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission requirements, Validation of saliva as a sample type, FDA review process
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: Can a high-complexity lab perform saliva sample validation under their CLIA license?
CLARIFIED ANSWER: FDA advises high-complexity labs to discuss saliva sample validation with the agency to ensure data adequacy. Certain variables related to saliva are not fully understood, and some data are unsuitable for clinical use.
VERBATIM QUESTION: Can a high-complexity lab perform saliva sample validation under their CLIA license?
VERBATIM ANSWER: Yes. So that frequently involves a collection device that is not formally covered under you know, the COVID-19 diagnostic situation. We have also seen data from saliva that is not really good enough for clinical use. So we are currently asking developers who want to utilize saliva -- and we do encourage it because we obviously already authorized one such test -- to come in and discuss their design with us and make sure that whatever data is generated it's FDA going to be sufficient for us to say yes, that looks good. And, you know, until such a time that we can define the true performance of saliva and we can predict the performance, we think this is the safest way to go right now. And there is - some of the data is just not good enough to support it and we don't know all the variables such as how do you need to preserve it, how do you store it, how do you transport it, and how do you extract it. And then what particular tests perform well on saliva-based samples.
SPEAKER QUESTION: Karen Richards
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva sample validation, high-complexity labs, CLIA license requirements
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: What requirements or data does the FDA expect when a developer discusses saliva testing designs with them?
CLARIFIED ANSWER: FDA requests that developers using saliva work with them to ensure generated data is sufficient, addressing variables like preservation, storage, transport, extraction, and test compatibility.
VERBATIM QUESTION: What requirements or data does the FDA expect when a developer discusses saliva testing designs with them?
VERBATIM ANSWER: Yes. So that frequently involves a collection device that is not formally covered under you know, the COVID-19 diagnostic situation. We have also seen data from saliva that is not really good enough for clinical use. So we are currently asking developers who want to utilize saliva -- and we do encourage it because we obviously already authorized one such test -- to come in and discuss their design with us and make sure that whatever data is generated it's FDA going to be sufficient for us to say yes, that looks good. And, you know, until such a time that we can define the true performance of saliva and we can predict the performance, we think this is the safest way to go right now. And there is - some of the data is just not good enough to support it and we don't know all the variables such as how do you need to preserve it, how do you store it, how do you transport it, and how do you extract it. And then what particular tests perform well on saliva-based samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva testing, FDA requirements, data sufficiency
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: What steps are advised to ensure saliva samples are properly preserved during collection?
CLARIFIED ANSWER: FDA advises developers using saliva samples to consult with the agency to ensure sufficient data. Saliva sample preservation, storage, and transport protocols, among others, are not yet fully defined.
VERBATIM QUESTION: What steps are advised to ensure saliva samples are properly preserved during collection?
VERBATIM ANSWER: We are currently asking developers who want to utilize saliva -- and we do encourage it because we obviously already authorized one such test -- to come in and discuss their design with us and make sure that whatever data is generated it's FDA going to be sufficient for us to say yes, that looks good. And, you know, until such a time that we can define the true performance of saliva and we can predict the performance, we think this is the safest way to go right now. And there is - some of the data is just not good enough to support it and we don't know all the variables such as how do you need to preserve it, how do you store it, how do you transport it, and how do you extract it.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva sample preservation, FDA consultation, saliva-based diagnostics
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: What are FDA recommendations for saliva sample storage conditions?
CLARIFIED ANSWER: FDA suggests developers discuss saliva sample designs with the agency to ensure sufficient data quality and performance since there are unresolved variables, including storage conditions.
VERBATIM QUESTION: What are FDA recommendations for saliva sample storage conditions?
VERBATIM ANSWER: We are currently asking developers who want to utilize saliva -- and we do encourage it because we obviously already authorized one such test -- to come in and discuss their design with us and make sure that whatever data is generated it's FDA going to be sufficient for us to say yes, that looks good. And, you know, until such a time that we can define the true performance of saliva and we can predict the performance, we think this is the safest way to go right now. And there is - some of the data is just not good enough to support it and we don't know all the variables such as how do you need to preserve it, how do you store it, how do you transport it, and how do you extract it.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva sample storage, FDA recommendations, diagnostic test validation
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: What guidance does the FDA provide regarding the transportation of saliva samples?
CLARIFIED ANSWER: FDA is advising developers to consult with them to ensure saliva sample transportation and other variables are adequately validated, as the current data is insufficient and inconsistent.
VERBATIM QUESTION: What guidance does the FDA provide regarding the transportation of saliva samples?
VERBATIM ANSWER: We have also seen data from saliva that is not really good enough for clinical use. So we are currently asking developers who want to utilize saliva -- and we do encourage it because we obviously already authorized one such test -- to come in and discuss their design with us and make sure that whatever data is generated it's FDA going to be sufficient for us to say yes, that looks good. And, you know, until such a time that we can define the true performance of saliva and we can predict the performance, we think this is the safest way to go right now. And there is - some of the data is just not good enough to support it and we don't know all the variables such as how do you need to preserve it, how do you store it, how do you transport it, and how do you extract it. And then what particular tests perform well on saliva-based samples.
SPEAKER QUESTION: Karen Richards
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva sample transportation, guidance for developers, COVID-19 test validation
REVIEW FLAG: False

QA Block 10-7
CLARIFIED QUESTION: What are the FDA's expectations for saliva sample extraction methods?
CLARIFIED ANSWER: FDA expects developers to consult with them regarding saliva sample design, ensuring data sufficiency. Key considerations include saliva preservation, storage, transport, and extraction methods, along with compatibility of tests for saliva.
VERBATIM QUESTION: What are the FDA's expectations for saliva sample extraction methods?
VERBATIM ANSWER: So we are currently asking developers who want to utilize saliva -- and we do encourage it because we obviously already authorized one such test -- to come in and discuss their design with us and make sure that whatever data is generated it's FDA going to be sufficient for us to say yes, that looks good. And, you know, until such a time that we can define the true performance of saliva and we can predict the performance, we think this is the safest way to go right now. And there is - some of the data is just not good enough to support it and we don't know all the variables such as how do you need to preserve it, how do you store it, how do you transport it, and how do you extract it. And then what particular tests perform well on saliva-based samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva sample methods, FDA expectations, Test validation
REVIEW FLAG: False

QA Block 10-8
CLARIFIED QUESTION: Which diagnostic tests are known to perform well with saliva as a sample type?
CLARIFIED ANSWER: FDA has authorized one test for saliva, but generally, FDA needs developers to discuss their designs and provide sufficient data since saliva's performance and variables are not fully defined yet.
VERBATIM QUESTION: Which diagnostic tests are known to perform well with saliva as a sample type?
VERBATIM ANSWER: We have also seen data from saliva that is not really good enough for clinical use. So we are currently asking developers who want to utilize saliva -- and we do encourage it because we obviously already authorized one such test -- to come in and discuss their design with us and make sure that whatever data is generated it's FDA going to be sufficient for us to say yes, that looks good. And, you know, until such a time that we can define the true performance of saliva and we can predict the performance, we think this is the safest way to go right now.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva-based diagnostic tests, FDA authorization, performance validation
REVIEW FLAG: False


#### 11. Assessing Serological Test Performance and Population Prevalence Accuracy

QA Block 11-1
CLARIFIED QUESTION: How do we gauge the true positive rate of a test in the population?
CLARIFIED ANSWER: The FDA suggests using serological tests with different antigens, particularly high-performing IgG tests, to gauge the true positive rate of a test. This approach provides a more accurate estimate of prevalence in the population. Leveraging statistics, applying a 95% confidence interval, and using the lower bound of sensitivity and specificity calculations ensures conservative accuracy.
VERBATIM QUESTION: How do we gauge the true positive rate of a test in the population?
VERBATIM ANSWER: Extensive molecular tests could help but that only tells you a snapshot of time for when patients are shedding detectable virus and the assay performs well enough. Serological means are probably the better means of assessing what the true prevalence is in a given population. Some of the studies I've seen may be limited to the performance of just one FDA maybe point-of-care test for which the true performance characteristics, the true specificity may not be entirely known. And so when you do an assessment you may say we just did a hundred samples. They were all negative. Therefore, our specificity is 100%. But that may or may not be the case. Using statistics, the application of a 95% confidence interval to the data set is important. And so the more data that you have, the more assurance you know what the performance is. I would postulate though that the best way to assess prevalence through serological testing means is to take two very high-performing but different tests that utilize different antigens -- not the same antigen -- to detect these antibodies. You may limit yourself to IgG, which is probably the most important antibody. IgM presents some difficulties maybe even in specificity sometimes. So if you look at two high-performing IgG tests -- and it might be just the IgG component of a combined test -- and if they are both positive, your certainty around whether the assessment of prevalence in the population is going to be much greater. If you choose tests that have relatively high sensitivity, you're not going to lose a lot of sensitivity in requiring the due positive. For example, even if the sensitivity for the two tests is only 90% your overall sensitivity for requiring the combined positive results only falls to about 81%. So obviously the higher the sensitivity for each of those two serological tests, the lower your sensitivity falls. But knowing the true performance on a lot of samples for these serological tests will give you a better estimate of what the range of performance characteristics are and you can take that into account. But again FDA thinks to be conservative you ought to take the lower bound of the 95% confidence level and not go any higher than that for both sensitivity and specificity calculations.
SPEAKER QUESTION: Daniel Schultz
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: True positive rate, Serological testing, Statistical methods
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: What measures are being used to gauge the true positive rate of COVID-19 diagnostics?
CLARIFIED ANSWER: The FDA recommends serological testing as a more reliable method for assessing true positive rates compared to molecular testing, which only captures a snapshot in time. Using two high-performing IgG tests with different antigens can enhance accuracy and certainty. Statistical application, such as employing a 95% confidence interval and focusing on the lower bound for sensitivity and specificity calculations, helps ensure reliable results in estimating true prevalence.
VERBATIM QUESTION: What measures are being used to gauge the true positive rate of COVID-19 diagnostics?
VERBATIM ANSWER: Extensive molecular tests could help but that only tells you a snapshot of time for when patients are shedding detectable virus and the assay performs well enough. Serological means are probably the better means of assessing what the true prevalence is in a given population. Some of the studies I've seen may be limited to the performance of just one FDA maybe point-of-care test for which the true performance characteristics, the true specificity may not be entirely known. And so when you do an assessment you may say we just did a hundred samples. They were all negative. Therefore, our specificity is 100%. But that may or may not be the case. Using statistics, the application of a 95% confidence interval to the data set is important. And so the more day that you have, the more assurance you know what the performance is. I would postulate though that the best way to assess prevalence through serological testing means is to take two very high-performing but different tests that utilize different antigens -- not the same antigen -- to detect these antibodies. You may limit yourself to IgG, which is probably the most important antibody. IgM presents some difficulties maybe even in specificity sometimes. So if you look at two high-performing IgG tests -- and it might be just the IgG component of a combined test -- and if they are both positive, your degree of certainty around whether the assessment of prevalence in the population is going to be much greater. If you choose to test that have relatively high sensitivity, you're not going to lose a lot of sensitivity in requiring the due positive. For example, even if the sensitivity for the two tests is only 90% your overall sensitivity for requiring the combined positive results only falls to about 81%. So obviously the higher the sensitivity for each of those two serological tests, the lower your sensitivity falls. But knowing you know, the true performance on a lot of samples for these serological tests will give you a better estimate of what the range of performance characteristics are and you can take that into account. But again I FDA think to be conservative you ought to take the lower bound of the 95% confidence level and not go any higher than that for both sensitivity and specificity calculations. Hopefully that helps.
SPEAKER QUESTION: Daniel Schultz
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: true positive rate, serological testing, 95% confidence interval
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: What are the methods being used to gauge the true positive rate if there is a lack of autopsies and tissue sampling?
CLARIFIED ANSWER: Serological testing using different high-performing antibody tests, especially IgG tests, is the preferred method to gauge true positive rates in populations when autopsies and tissue sampling are absent. Confidence intervals and statistical models are essential to evaluate test performance.
VERBATIM QUESTION: What are the methods being used to gauge the true positive rate if there is a lack of autopsies and tissue sampling?
VERBATIM ANSWER: Extensive molecular tests could help but that only tells you a snapshot of time for when patients are shedding detectable virus and the assay performs well enough. Serological means are probably the better means of assessing what the true prevalence is in a given population. Some of the studies I've seen may be limited to the performance of just one FDA maybe point-of-care test for which the true performance characteristics, the true specificity may not be entirely known. And so when you do an assessment you may say we just did a hundred samples. They were all negative. Therefore, our specificity is 100%. But that may or may not be the case. Using statistics, the application of a 95% confidence interval to the data set is important. And so the more day that you have, the more assurance you know what the performance is. I would postulate though that the best way to assess prevalence through serological testing means is to take two very high-performing but different tests that utilize different antigens -- not the same antigen -- to detect these antibodies. You may limit yourself to IgG, which is probably the most important antibody. IgM presents some difficulties maybe even in specificity sometimes. So if you look at two high-performing IgG tests -- and it might be just the IgG component of a combined test -- and if they are both positive, your  of certainty around whether the assessment of prevalence in the population is going to be much greater. If you choose to test that have relatively high sensitivity, you're not going to lose a lot of sensitivity in requiring the due positive. For example, even if the sensitivity for the two tests is only 90% your overall sensitivity for requiring the combined positive results only falls to about 81%. So obviously the higher the sensitivity for each of those two serological tests, the lower your sensitivity falls. But knowing you know, the true performance on a lot of samples for these serological tests will give you a better estimate of what the range of performance characteristics are and you can take that into account. But again I FDA think to be conservative you ought to take the lower bound of the 95% confidence level and not go any higher than that for both sensitivity and specificity calculations. Hopefully that helps.
SPEAKER QUESTION: Daniel Schultz
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: True positive rate, Serological testing, Test performance evaluation
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: What statistical considerations should be applied when evaluating specificity and sensitivity data for serological tests?
CLARIFIED ANSWER: Statistical considerations for serological tests include using a 95% confidence interval to evaluate specificity and sensitivity, utilizing two high-performing tests with different antigens to increase certainty, and focusing on IgG antibodies. To be conservative, the lower bound of the 95% confidence interval should be used in calculations.
VERBATIM QUESTION: What statistical considerations should be applied when evaluating specificity and sensitivity data for serological tests?
VERBATIM ANSWER: Yes. Extensive molecular tests could help but that only tells you a snapshot of time for when patients are shedding detectable virus and the assay performs well enough. Serological means are probably the better means of assessing what the true prevalence is in a given population. Some of the studies I've seen may be limited to the performance of just one FDA maybe point-of-care test for which the true performance characteristics, the true specificity may not be entirely known. And so when you do an assessment you may say we just did a hundred samples. They were all negative. Therefore, our specificity is 100%. But that may or may not be the case. Using statistics, the application of a 95% confidence interval to the data set is important. And so the more day that you have, the more assurance you know what the performance is. I would postulate though that the best way to assess prevalence through serological testing means is to take two very high- performing but different tests that utilize different antigens -- not the same antigen -- to detect these antibodies. You may limit yourself to IgG, which is probably the most important antibody. IgM presents some difficulties maybe even in specificity sometimes. So if you look at two high-performing IgG tests -- and it might be just the IgG component of a combined test -- and if they are both positive, your  of certainty around whether the assessment of prevalence in the population is going to be much greater. If you choose to test that have relatively high sensitivity, you're not going to lose a lot of sensitivity in requiring the due positive. For example, even if the sensitivity for the two tests is only 90% your overall sensitivity for requiring the combined positive results only falls to about 81%. So obviously the higher the sensitivity for each of those two serological tests, the lower your sensitivity falls. But knowing you know, the true performance on a lot of samples for these serological tests will give you a better estimate of what the range of performance characteristics are and you can take that into account. But again I FDA think to be conservative you ought to take the lower bound of the 95% confidence level and not go any higher than that for both sensitivity and specificity calculations. Hopefully that helps.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serological test sensitivity, Specificity assessment, Confidence intervals
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: Why is it important to use two different serological tests that detect distinct antigens when assessing prevalence?
CLARIFIED ANSWER: Using two serological tests that detect distinct antigens improves certainty in determining prevalence, as it reduces the likelihood of errors by requiring both tests to confirm positive results. Focus on IgG tests is recommended due to their reliability.
VERBATIM QUESTION: Why is it important to use two different serological tests that detect distinct antigens when assessing prevalence?
VERBATIM ANSWER: I would postulate though that the best way to assess prevalence through serological testing means is to take two very high- performing but different tests that utilize different antigens -- not the same antigen -- to detect these antibodies. You may limit yourself to IgG, which is probably the most important antibody. IgM presents some difficulties maybe even in specificity sometimes. So if you look at two high-performing IgG tests -- and it might be just the IgG component of a combined test -- and if they are both positive, your  of certainty around whether the assessment of prevalence in the population is going to be much greater.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serological testing, Distinct antigens, Prevalence assessment
REVIEW FLAG: False

QA Block 11-6
CLARIFIED QUESTION: What are the implications of selecting IgG over IgM for serological testing purposes?
CLARIFIED ANSWER: The FDA explains that IgG is preferred over IgM for serological testing because IgM has potential specificity issues. Using two high-performing IgG tests, with different antigens, allows for a more accurate assessment of population prevalence.
VERBATIM QUESTION: What are the implications of selecting IgG over IgM for serological testing purposes?
VERBATIM ANSWER: Serological means are probably the better means of assessing what the true prevalence is in a given population. I would postulate though that the best way to assess prevalence through serological testing means is to take two very high-performing but different tests that utilize different antigens -- not the same antigen -- to detect these antibodies. You may limit yourself to IgG, which is probably the most important antibody. IgM presents some difficulties maybe even in specificity sometimes. So if you look at two high-performing IgG tests -- and it might be just the IgG component of a combined test -- and if they are both positive, your  of certainty around whether the assessment of prevalence in the population is going to be much greater.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serological Testing, IgG vs IgM, Antibody Testing
REVIEW FLAG: False

QA Block 11-7
CLARIFIED QUESTION: How does the combination of sensitivity rates impact overall sensitivity when using multiple serological tests?
CLARIFIED ANSWER: Using two high-performing serological tests that detect different antigens can improve certainty in assessing prevalence. Even if both tests have 90% sensitivity, the combined sensitivity would be around 81%. Higher sensitivity tests further minimize this drop.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: I would postulate though that the best way to assess prevalence through serological testing means is to take two very high-performing but different tests that utilize different antigens -- not the same antigen -- to detect these antibodies. You may limit yourself to IgG, which is probably the most important antibody. IgM presents some difficulties maybe even in specificity sometimes. So if you look at two high-performing IgG tests -- and it might be just the IgG component of a combined test -- and if they are both positive, your degree of certainty around whether the assessment of prevalence in the population is going to be much greater. If you choose to test that have relatively high sensitivity, you're not going to lose a lot of sensitivity in requiring the due positive. For example, even if the sensitivity for the two tests is only 90% your overall sensitivity for requiring the combined positive results only falls to about 81%. So obviously the higher the sensitivity for each of those two serological tests, the lower your sensitivity falls.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serological test sensitivity, Combination of tests, Prevalence estimation
REVIEW FLAG: False

QA Block 11-8
CLARIFIED QUESTION: What is the significance of applying a 95% confidence interval to sensitivity and specificity calculations?
CLARIFIED ANSWER: Applying a 95% confidence interval ensures a more reliable estimate of test performance, and the FDA advises using the lower bound to be conservative for sensitivity and specificity calculations.
VERBATIM QUESTION: What is the significance of applying a 95% confidence interval to sensitivity and specificity calculations?
VERBATIM ANSWER: Using statistics, the application of a 95% confidence interval to the data set is important. And so the more data that you have, the more assurance you know what the performance is. ... But again I FDA think to be conservative you ought to take the lower bound of the 95% confidence level and not go any higher than that for both sensitivity and specificity calculations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 95% confidence interval, test sensitivity, test specificity
REVIEW FLAG: False

QA Block 11-9
CLARIFIED QUESTION: Why does the FDA recommend using the lower bound of the confidence interval for estimating sensitivity and specificity?
CLARIFIED ANSWER: The FDA recommends using the lower bound of the 95% confidence interval for sensitivity and specificity calculations to ensure a conservative and reliable estimate.
VERBATIM QUESTION: Why does the FDA recommend using the lower bound of the confidence interval for estimating sensitivity and specificity?
VERBATIM ANSWER: But again I FDA think to be conservative you ought to take the lower bound of the 95% confidence level and not go any higher than that for both sensitivity and specificity calculations. Hopefully that helps.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sensitivity and specificity, 95% confidence interval, conservative estimation
REVIEW FLAG: False

### removed qa blocks
QA Block 1-11
CLARIFIED QUESTION: What level of sensitivity and specificity does the FDA recommend for serology tests aiming for lay user use in point of care settings?
CLARIFIED ANSWER: The FDA has not yet authorized any serology tests for point-of-care settings due to insufficient data showing their accuracy in lay-user hands.
VERBATIM QUESTION: What level of sensitivity and specificity does the FDA recommend for serology tests aiming for lay user use in point of care settings?
VERBATIM ANSWER: To date we have authorized four serology tests. None of them yet are point of care even though some of them are designed to be performed in the near-patient point of care setting. And this is because data has not yet been submitted for anything that we could authorize yet that shows accurate testing in the lay user hands. That is usually the point of care patient setting. These lay user studies are important as outside of trained laboratory professionals performing testing, we want to ensure that accurate test results are obtained.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology tests, Point of care use, Lay user accuracy
REVIEW FLAG: False

QA Block 1-18
CLARIFIED QUESTION: Are manufacturers required to combine serology tests to achieve higher positive predictive values in low prevalence scenarios?
CLARIFIED ANSWER: The FDA is examining the impact of combining two serology tests to improve positive predictive values in low prevalence populations. This approach is not mandatory but demonstrates that using two highly specific tests sequentially can significantly enhance positive predictive values.
VERBATIM QUESTION: Are manufacturers required to combine serology tests to achieve higher positive predictive values in low prevalence scenarios?
VERBATIM ANSWER: One thing that we're examining is if you combine two serology tests back-to-back and you require a positive for both serology tests, how does that impact the positive predictive value. If you take two highly specific tests and that FDA same lower and bound of the confidence interval is 99% and you have the same 1% population, the positive predictive value rises to 98.9% -- a pretty decent number. Even if you start out with the lower serology test that has a specificity of 95% but follow it up with a more specific test such as 99% specific in a 1% prevalent population, your positive predictive value rises to 94.5%. So just under 95% -- also a fairly decent number.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology tests, Positive predictive value, Diagnostic accuracy
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: What steps can labs take to verify the Abbott ID Now test in the absence of patient samples?
CLARIFIED ANSWER: Labs can verify the Abbott ID Now test by contriving samples, such as diluting a known positive patient sample to a low positive and applying it to swabs for testing.
VERBATIM QUESTION: What steps can labs take to verify the Abbott ID Now test in the absence of patient samples?
VERBATIM ANSWER: Yes. So you could contrive samples in the lab to verify testing. So take a known positive patient sample from VTM...understand, you know, where the range of positivity is if you have a molecular test that gives you cycle thresholds. Find something near, you know, a low positive or dilute it down to a low positive. You can then pipe that on to swabs in replicates and test that in the Abbott ID Now. That would be one possible way to verify performance of the Abbott ID Now in your hands with not having to go ahead and actually swab patients and swab enough patients that you get a positive patient to compare.
SPEAKER QUESTION: Cynthia Flynn
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Abbott ID Now test verification, contrived patient samples for labs
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2024-12-31 13:01:15 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 11
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What are the specific validation steps required for using Q-tip style cotton swabs in COVID-19 testing?
QI 1-2: Does a developer need to validate changes to their swab media if using a new manufacturer's alternative product?
QI 1-3: What are the requirements for laboratories to modify PCR instruments under their CLIA SOPs without needing a EUA update?
QI 1-4: In the absence of a EUA update requirement, what kind of bridging study is acceptable for labs modifying their swab media or reagents?
QI 1-5: When will updated instructions for Abbott ID Now tests reflecting removal of VTM as a sample type be available?
QI 1-6: Are there new specific optional extraction chemistries added to the FDA-approved list for COVID-19 tests?
QI 1-7: Are there additional requirements for submitting voluntary validations of alternate cotton swab types to the FDA?
QI 1-8: What considerations must be evaluated for saliva as a sample type to gain regulatory approval for COVID-19 testing?
QI 1-9: What are the FDA's expectations regarding home collection kits before launching them under EUA?
QI 1-10: Can two serology tests be combined to improve positive predictive value, and what performance results would be acceptable for this setup?
QI 1-11: What level of sensitivity and specificity does the FDA recommend for serology tests aiming for lay user use in point of care settings?
QI 1-12: How does the FDA prioritize complaints about tests and address incidents leading to concerns about product performance or fraud?
QI 1-13: What's the role of 95% confidence interval lower bounds in the performance evaluation of serology tests?
QI 1-14: How is the public-private partnership led by the FDA improving terminology consistency for diagnostic test reporting (such as SARS-CoV-2)?
QI 1-15: What standardization steps are required to describe SARS-CoV-2 diagnostic and serology tests for interoperability across laboratories?
QI 1-16: What are the expected performance levels of specificity and sensitivity in serology tests for lower prevalence populations, according to the FDA?
QI 1-17: What is the timeline for the FDA's release of its serology testing template on the EUA website?
QI 1-18: Are manufacturers required to combine serology tests to achieve higher positive predictive values in low prevalence scenarios?
QI 1-19: Are there international efforts guided by FDA to harmonize the testing validation of serological and other COVID-19-related diagnostics?
QI 1-20: What methodology is being utilized in the interagency collaboration to streamline EUA for serology tests validated as high-performing?

#### Section 2 of 11
##### Explicit Questions Extraction
QE 2-1: Will a pathway be created for home COVID-19 tests?
QE 2-2: Is there an estimate for when templates for home collection and home testing might be ready?

##### Implicit Questions Extraction
QI 2-1: What steps should developers take while awaiting finalized templates for home collection and home testing?
QI 2-2: How can developers engage with the FDA to address challenges in home test designs?
QI 2-3: What specific elements are being considered by the FDA to balance accuracy and safety of home testing templates?

#### Section 3 of 11
##### Explicit Questions Extraction
QE 3-1: Are you still taking the position that there is no scientific evidence that capillary blood is equal to venipuncture blood for rapid serology test kits?
QE 3-2: Are you still taking the position that licensed health professionals like physicians, nurse practitioners, or PAs cannot administer rapid test kits outside of a CLIA complex lab?

##### Implicit Questions Extraction
QI 3-1: What data is required to demonstrate the equivalency between venipuncture and fingerstick blood for COVID-19 serology tests?
QI 3-2: What is the minimum number of patients needed in studies to show sample type equivalency for serology tests?
QI 3-3: What information will be included in the FDA serology templates for developers?
QI 3-4: Can a developer submit data for tests that include fingerstick as an alternative sample type?
QI 3-5: What are the specific post-market study requirements for tests involving fingersticks?
QI 3-6: What performance data is required to authorize tests that use lay users or non-laboratorians?

#### Section 4 of 11
##### Explicit Questions Extraction
QE 4-1: Where will there be prioritization of serology tests that can perform high-specificity and high-sensitivity point-of-care testing in the coming weeks and this year?

##### Implicit Questions Extraction
QI 4-1: What are the data requirements for demonstrating that accurate testing can be performed in a point-of-care setting by non-laboratory professionals?
QI 4-2: What is needed to demonstrate the equivalency of a fingerstick sample and other evaluated sample types for point-of-care tests?
QI 4-3: What are the minimum performance characteristics required in the FDA template for authorizing point-of-care tests?
QI 4-4: How should developers address low specificity in their serology tests, and what cross-reactivity testing may be required?
QI 4-5: Why might even highly specific serology tests require confirmatory testing for clinical decision-making?
QI 4-6: Under what conditions might the FDA accept slightly lower performance for point-of-care tests if they are paired with confirmatory central lab testing?

#### Section 5 of 11
##### Explicit Questions Extraction
QE 5-1: How can labs verify the Abbott ID Now test if they can only use a direct swab method, given that instructions for this are not in the package insert?
QE 5-2: Are you going to conduct plaque studies during serology studies to evaluate whether true neutralizing antibodies are detected?

##### Implicit Questions Extraction
QI 5-1: What steps can labs take to verify the Abbott ID Now test in the absence of patient samples?
QI 5-2: Can positive patient samples in VTM be diluted to create low positive controls for validation of the Abbott ID Now test?
QI 5-3: How can interfering substances present in nasal swabs be tested when verifying the Abbott ID Now test?
QI 5-4: Is there a recommended approach to correlating neutralizing antibodies with total antibody detection in serology tests?
QI 5-5: What challenges exist in designing tests to specifically measure neutralizing antibodies?
QI 5-6: Why doesn't the detection of antibodies through serology tests equate to confirmed immunity against infection?

#### Section 6 of 11
##### Explicit Questions Extraction
QE 6-1: What is the progress on the FDA template for rapid viral detection immunoassays?
QE 6-2: Are there any concerns about detection and comparison using molecular tests as the comparator method?

##### Implicit Questions Extraction
QI 6-1: What is the expected performance standard for rapid antigen tests compared to molecular assays?
QI 6-2: Does the FDA have specific recommendations for using anterior nares samples in rapid antigen testing?
QI 6-3: Should the performance of rapid antigen tests be benchmarked against existing standards for flu detection?
QI 6-4: What is the FDA's perspective on rapid antigen tests' plausibility based on anterior nares viral load?
QI 6-5: What specific criteria should labs or healthcare professionals consider when evaluating rapid antigen test performance?

#### Section 7 of 11
##### Explicit Questions Extraction
QE 7-1: Would it be helpful if we prepared a template for home use serology testing?
QE 7-2: For the home usability testing for pixel, can you share whether you required 15 laypeople for the study?
QE 7-3: Was the pixel study a clinical home usability study with clinical endpoints or just a pure usability study with no clinical endpoint?

##### Implicit Questions Extraction

#### Section 8 of 11
##### Explicit Questions Extraction
QE 8-1: Is it acceptable to use only five out of the recommended seven samples for cross-reactivity testing for an IgM and IgG antibody test?
QE 8-2: How can we demonstrate that our test can detect both IgG and IgM antibodies?
QE 8-3: Can we use the FDA template for validation even if our current validation is incorrect?

##### Implicit Questions Extraction
QI 8-1: What are the minimum acceptable numbers of samples needed for cross-reactivity testing if seven cannot be acquired?
QI 8-2: Are pre-COVID-19 samples acceptable for cross-reactivity testing, and are there limitations on their use?
QI 8-3: What constitutes recent exposure to respiratory pathogens when selecting negative samples for cross-reactivity testing?
QI 8-4: Can prior studies using well-characterized antibodies be reused to demonstrate class specificity?
QI 8-5: Does the FDA provide a specific list of acceptable chemical methods for demonstrating class specificity?
QI 8-6: What steps should a developer take if validation is completed, but their study designs do not fully meet the FDA's expectations?
QI 8-7: Can a test remain on the market after validation if inaccuracies are identified during FDA review?

#### Section 9 of 11
##### Explicit Questions Extraction
QE 9-1: If you have an EUA, would you be cleared for non-CLIA laboratories to use?
QE 9-2: Since the FDA doesn't control CLIA, what is the mechanism for using tests in non-CLIA laboratories?

##### Implicit Questions Extraction
QI 9-1: What does the FDA mean by "pathway C or D," and how do developers notify the FDA through these pathways?
QI 9-2: What criteria does the FDA use to assess whether a test is suitable for moderate complexity or waived settings?
QI 9-3: How does the FDA determine and assign deemed status for test complexity during an emergency use situation?
QI 9-4: What information does the FDA include in its authorization letters regarding test complexity determinations?
QI 9-5: Where on the FDA's website can developers find the updated complexity categorizations of authorized tests?

#### Section 10 of 11
##### Explicit Questions Extraction
QE 10-1: Does the FDA require a EUA submission if a high-complexity lab using a FDA-approved EUA molecular test for respiratory specimens wants to validate and use saliva as a sample type?
QE 10-2: Can a high-complexity lab perform saliva sample validation under their CLIA license?

##### Implicit Questions Extraction
QI 10-1: What requirements or data does the FDA expect when a developer discusses saliva testing designs with them?
QI 10-2: What steps are advised to ensure saliva samples are properly preserved during collection?
QI 10-3: What are FDA recommendations for saliva sample storage conditions?
QI 10-4: What guidance does the FDA provide regarding the transportation of saliva samples?
QI 10-5: What are the FDA's expectations for saliva sample extraction methods?
QI 10-6: Which diagnostic tests are known to perform well with saliva as a sample type?

#### Section 11 of 11
##### Explicit Questions Extraction
QE 11-1: How do we gauge the true positive rate of a test in the population?
QE 11-2: What measures are being used to gauge the true positive rate of COVID-19 diagnostics?
QE 11-3: What are the methods being used to gauge the true positive rate if there is a lack of autopsies and tissue sampling?

##### Implicit Questions Extraction
QI 11-1: What statistical considerations should be applied when evaluating specificity and sensitivity data for serological tests?
QI 11-2: Why is it important to use two different serological tests that detect distinct antigens when assessing prevalence?
QI 11-3: What are the implications of selecting IgG over IgM for serological testing purposes?
QI 11-4: How does the combination of sensitivity rates impact overall sensitivity when using multiple serological tests?
QI 11-5: What is the significance of applying a 95% confidence interval to sensitivity and specificity calculations?
QI 11-6: Why does the FDA recommend using the lower bound of the confidence interval for estimating sensitivity and specificity?
